

Supporting Information

Rh(III)-Catalyzed Regioselective Versatile Indole Derivatization: Delivering Potential of Rare β -(1*H*-Indol-2-yl)- β -Amino Acids in One Pot

Shuaizhong Zhang,[†] Jinquan Zhang[†] and Hongbin Zou^{*}

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China

^{*} Corresponding Author. Email: zouhb@zju.edu.cn

Table of Contents

1. General Information.....	S3
2. Experimental Section.....	S3
2.1 Substrates Preparation.....	S3
2.2 Preliminary Optimization of Reaction Conditions.....	S5
2.3 General Procedures.....	S7
3. Characterization Data.....	S10
4. Synthetic Applications.....	S39
4.1 Hydrolysis of 3a	S39
4.2 Hydrolysis of 4aa	S40
5. Mechanism Study.....	S41
5.1 Effect of NH on C-H Bond Activation.....	S41
5.2 Preparation of Rhodacycle 9	S42
5.3 9 Leading to Products 3a and 4a	S43
5.4 Effect of AgSbF ₆ on C-H Bond Activation.....	S44
5.5 KIE Experiments.....	S45
5.6 Deuterium Labeling Experiment.....	S46
5.7 The Synthesis of Ortho Alkenylated Complex E	S47
6. References.....	S49
7. NMR Spectra.....	S50


1. General Information

Catalytic reactions were carried out in Schlenk tubes using pre-dried glassware. Acrylates (2) were synthesized according to previously described procedures¹. Commercially available reagents were purchased from Energy Chemical, Bidepharm, Sigma Aldrich, Alfa Aesar, Acros or TCI, and used without purification unless otherwise noted. Column chromatography purification was performed using 200–300 mesh silica gel. NMR spectra were mostly recorded for ¹H NMR at 500 MHz and for ¹³C NMR at 125 MHz. CDCl₃ and DMSO-*d*₆ were used as solvents. Chemical shifts were referenced relative to residual solvent signal (CDCl₃: ¹H NMR: δ 7.26 ppm, ¹³C NMR: δ 77.16 ppm; DMSO-*d*₆: ¹H NMR: δ 2.50 ppm, ¹³C NMR: δ 39.52 ppm). The following abbreviations are used to describe peak patterns where appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Coupling constants (*J*) are reported in Hertz (Hz). HRMS was performed on Agilent Technologies 6224 TOF LC/MS apparatus (ESI).

2. Experimental Section

2.1 Substrates Preparation


2.1.1 Preparation of *N*-acetyl-1*H*-indole-1-carboxamide derivatives (Method A)



Step 1: A reaction tube (100 mL) with magnetic stir bar was charged with indole (5.0 mmol, 1.0 equiv.), 1,1'-carbonyldiimidazole (CDI, 7.5 mmol, 1.5 equiv.) and 4-dimethylaminepyridine (DMAP, 5.0 mol%). Then 25 mL anhydrous acetonitrile was added to the reaction tube. The reaction system was stirred at 85 °C oil bath for 10 h. After cooling to room temperature, ammonium hydroxide (15.0 mmol) was added and then the reaction was stirred at 60 °C oil bath for another 6 h until most of indole was consumed by TLC detection. Then the reaction was cooled to room temperature and the reaction mixture was poured in 70 mL water and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine and dried over sodium sulphate. The solvent was removed under reduced pressure, and the solid obtained


was washed with ether to remove excess complexes to afford white 1*H*-indole-1-carboxamide.

Step 2: A reaction tube (100 mL) with magnetic stir bar was charged with 1*H*-indole-1-carboxamide (5.0 mmol, 1.0 equiv.), NEt₃ (15.0 mmol, 3.0 equiv.) and acetyl chloride (10.0 mmol, 2.0 equiv.). Then 20 mL anhydrous toluene was added to the reaction tube. The reaction system was stirred at 140 °C oil bath for 12 h. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to afford **1**.



Scheme S1 Preparation of substrates **1**.

2.1.2 Preparation of acrylate derivatives (Method B)¹




Alcohol or phenol derivative (3.0 mmol) was mixed with Et₃N (4.5 mmol) in dry CH₂Cl₂ (10 mL) and cooled to 0 °C in an ice-water bath. Then acryloyl chloride (3.6 mmol) was added dropwise. The mixture was warmed to room temperature and stirred overnight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (PET: EtOAc = 30:1) to get the desired product (80–96% yield).

2.2 Preliminary Optimization of Reaction Conditions

Our initial studies began with *N*-acetyl-1*H*-indole-1-carboxamide (**1a**) and phenyl acrylate (**2a**) by screening a wide range of reaction parameters, including catalysts, solvents, additives, and temperature (Table S1). Treating **1a** with **2a** in the presence of 5 mol% of [Cp**Rh*Cl₂]₂, 30 mol% of AgSbF₆, and 1.5 equiv of NaOAc in MeOH at 45 °C for 12 h provided the desired C(sp²)-H alkenylation-annulation product **3a** and alkenylation-elimination product **4a** with the yields of 21% and 28%, respectively (Table S1, entry 1). Changing the catalysts to Cp**Co*(CO)I₂ could also drive this alkenylation-annulation transformation with 8% yield (entry 2). Other catalyst such as [Cp**Ir*Cl₂]₂, [Cp**Ru*Cl₂]₂, and Pd(OAc)₂ failed to afford **3a** and **4a** (entry 3–5). Next, we also screened the solvent and found that dichloroethane(DCE) could also drive this reaction with slightly lower yield (entry 6). Notably, replacing MeOH with 2,2,2-trifluoroethanol(TFE) boosted the yield of **3a** to 37%, while the yield of **4a** decreased to 7%, which identified TFE as the best solvent for **3a** formation (entry 7). Further screening of AgSbF₆ showed that 20 mol% of AgSbF₆ resulted in the similar yield of **3a** than 30 mol% of AgSbF₆ (entry 7–10). Entry 11 showed that absence of NaOAc also resulted in a decrease in the production of **3a**. Since KHSO₄ has been reported to benefit similar cyclizations², we replaced NaOAc with NaOAc/KHSO₄ and the yield of **3a** increased to 68% (entry 12). However, substituting KHSO₄ with K₂S₂O₈ resulted in a slight decrease in the production of **3a** (entry 13). Further temperature screening showed that the yield of **3a** increased to 85% at 60 °C (entry 14), and a slight decrease was observed when the temperature continuously increased to 80 °C (entry 15). Interestingly, simple substitution of NaOAc (entry 1)

with CsOAc (entry 16) in MeOH resulted in a slightly decreased yield of **3a** and a significantly increased yield of **4a** to 57%. Next, we also tested the reaction temperature for **4a** formation, which indicated that 80 °C was the best choice for alkenylation–elimination of **1a** (entries 17 and 18).


Table S1. Optimization of Reaction Conditions of 3a and 4a^a



entry	catalyst(mol%)	solvent	additive	T (°C)	yield (%) ^b	
					3a	4a
1	[Cp*RhCl ₂] ₂	MeOH	AgSbF ₆ /NaOAc	45	21	28
2	Cp*Co(CO)I ₂	MeOH	AgSbF ₆ /NaOAc	45	8	<5
3	[Cp*IrCl ₂] ₂	MeOH	AgSbF ₆ /NaOAc	45	<5	<5
4	[Cp*RuCl ₂] ₂	MeOH	AgSbF ₆ /NaOAc	45	<5	<5
5	Pd(OAc) ₂	MeOH	NaOAc	45	<5	<5
6	[Cp*RhCl ₂] ₂	DCE	AgSbF ₆ /NaOAc	45	19	20
7	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc	45	37	7
8 ^c	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc	45	36	<5
9 ^d	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc	45	25	<5
10	[Cp*RhCl ₂] ₂	TFE	NaOAc	45	<5	<5
11	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆	45	8	<5
12	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc/KHSO ₄	45	68	<5
13	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc/K ₂ S ₂ O ₈	45	57	10
14	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc/KHSO ₄	60	85	<5
15	[Cp*RhCl ₂] ₂	TFE	AgSbF ₆ /NaOAc/KHSO ₄	80	72	12
16	[Cp*RhCl ₂] ₂	MeOH	AgSbF ₆ /CsOAc	45	18	57
17	[Cp*RhCl ₂] ₂	MeOH	AgSbF ₆ /CsOAc	60	13	68
18	[Cp*RhCl ₂] ₂	MeOH	AgSbF ₆ /CsOAc	80	8	76

^aReaction conditions: **1a** (0.2 mmol), **2a** (0.6 mmol), [Cp*RhCl₂]₂ (0.01 mmol), AgSbF₆ (0.06 mmol), additive (0.3 mmol), and solvent (1 mL). ^bIsolated yield. ^c AgSbF₆ (0.04 mmol). ^d AgSbF₆ (0.02 mmol).

Our studies began with **3a** by screening a wide range of reaction parameters, including solvents, additives, temperature and reaction time (Table S2). The results showed that treating **3a** with KOH in THF/H₂O at 130 °C for 6 h are the most favorable condition for **5a** production.


Table S2. Optimization of Reaction Conditions of 5a^a

entry	solvent	additive	T (°C)	time	yield (%) ^b
1	THF/H ₂ O	K ₂ CO ₃	110	3 h	<5
2	THF/H ₂ O	NaOH	110	3 h	12
3	THF/H ₂ O	KOH	110	3 h	18
4	MeOH/H ₂ O	KOH	110	3 h	8
5	MeCN/H ₂ O	KOH	110	3 h	<5
6	THF/H ₂ O	KOH	90	3 h	<5
7	THF/H ₂ O	KOH	130	3 h	46
8	THF/H ₂ O	KOH	130	6 h	67
9	THF/H ₂ O	KOH	130	12 h	68

^aReaction conditions: **3a** (0.2 mmol), KOH (0.6 mmol), H₂O (1.0 mL), and other solvent; then BzCl (0.50 mmol) was added and reacted at 0 °C for 3 h. ^bIsolated yield.


2.3 General Procedures

2.3.1 Preparation of alkenylation–annulation products **3** (GP1)



A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl amide substituted indole **1** (0.20 mmol), acrylate **2** (0.60 mmol), [Cp^{*}RhCl₂]₂ (6 mg, 0.010 mmol), AgSbF₆ (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), KHSO₄ (41 mg, 0.30 mmol) and TFE (1.0 mL). The reaction was allowed to stir at 60 °C oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **3**.

2.3.2 Preparation of alkenylation–elimination products **4** (GP2)




A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl amide substituted indole **1** (0.20 mmol), acrylate **2** (0.60 mmol), $[\text{Cp}^*\text{RhCl}_2]_2$ (6 mg, 0.010 mmol), AgSbF_6 (21 mg, 0.060 mmol), CsOAc (57 mg, 0.30 mmol) and MeOH (1.0 mL). The reaction was allowed to stir at $80\text{ }^\circ\text{C}$ oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **4**.

2.3.3 Preparation of 3-benzamido-3-(1*H*-indol-2-yl)propanoic acid products **5a–5h** (GP3)




A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl amide substituted indole **1** (0.20 mmol), acrylate **2a** (89 mg, 0.60 mmol), $[\text{Cp}^*\text{RhCl}_2]_2$ (6 mg, 0.010 mmol), AgSbF_6 (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), KHSO_4 (41 mg, 0.30 mmol) and TFE (1.0 mL). The reaction was allowed to stir at $60\text{ }^\circ\text{C}$ oil bath for 12 h. After cooling to room temperature, KOH (56 mg, 1.0 mmol), H_2O (1.0 mL), and THF (2.0 mL) was added and the reaction was stirred at $130\text{ }^\circ\text{C}$ oil bath for another 3 h. After cooling to room temperature, BzCl (71 mg, 0.50 mmol) was added and then the reaction was stirred at $0\text{ }^\circ\text{C}$ for another 3 h. Then the reaction was poured in 20 mL 0.5 M HCl and extracted with ethyl acetate ($3 \times 10\text{ mL}$). The combined organic layers were washed with brine, and collected organic layers were dried over sodium sulphate. The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$) to afford the desired products **5a–5d**, **5g**, **5h**. However, substrates **1** with electron-withdrawing fluorine and chlorine groups couldn't afford the corresponding **5e** and **5f**.

2.3.4 Preparation of products 5a–5h from 3 (GP4)



A reaction tube (10 mL) with magnetic stir bar was charged with **3** (0.20 mmol) KOH (56 mg, 1.0 mmol), H₂O (1.0 mL), and THF (2.0 mL) was added and the reaction was stirred at 130 °C oil bath for another 6 h. After cooling to room temperature, BzCl (71 mg, 0.50 mmol) was added and then the reaction was stirred at 0 °C for another 3 h. Then the reaction was poured in 10 mL 0.5 M HCl and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine, and collected organic layers were dried over sodium sulphate. The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (CH₂Cl₂/MeOH) to afford the desired products **5a–5h**. However, **3y** and **3z** with electron-withdrawing fluorine and chlorine groups couldn't afford the corresponding **5e** and **5f**.


2.3.5 Preparation of 3-Boc-3-(1*H*-indol-2-yl)propanoic acid products 5i–5k (GP5)



A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl amide substituted indole **1** (0.20 mmol), acrylate **2a** (89 mg, 0.60 mmol), [Cp**RhCl*₂]₂ (6 mg, 0.010 mmol), AgSbF₆ (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), KHSO₄ (41 mg, 0.30 mmol) and TFE (1.0 mL). The reaction was allowed to stir at 60 °C oil bath for 12 h. After cooling to room temperature, KOH (56 mg, 1.0 mmol), H₂O (1.0 mL), and THF (2.0 mL) was added and the reaction was stirred at 130 °C oil bath for another 3 h. After cooling to room temperature, Boc₂O (109 mg, 0.50 mmol) was added and then the reaction was stirred at 0 °C for another 3 h. Then the reaction was poured in 30 mL 0.3 M HCl and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine, and collected organic layers were dried over sodium sulphate.


The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (CH₂Cl₂/MeOH) to afford the desired products **5i** and **5j**. However, substrate **1** with electron-withdrawing fluorine group couldn't afford the corresponding **5k**.

2.3.6 Preparation of products **5i–5k** from **3** (GP6)




A reaction tube (10 mL) with magnetic stir bar was charged with **3** (0.20 mmol) KOH (56 mg, 1.0 mmol), H₂O (1.0 mL), and THF (2.0 mL) was added and the reaction was stirred at 130 °C oil bath for another 6 h. After cooling to room temperature, Boc₂O (109 mg, 0.50 mmol) was added and then the reaction was stirred at 0 °C for another 3 h. Then the reaction was poured in 30 mL 0.3 M HCl and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine, and collected organic layers were dried over sodium sulphate. The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (CH₂Cl₂/MeOH) to afford the desired products **5i** and **5j**. However, **3y** with electron-withdrawing fluorine group couldn't afford the corresponding **5k**.


3. Characterization Data




N-Acetyl-1H-indole-1-carboxamide (1a): The title compound was obtained as a white solid (636 mg) in 63% yield according to the **Method A**. ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.99 (s, 1H), 8.20 (d, *J* = 9.0 Hz, 1H), 7.91 (d, *J* = 3.5 Hz, 1H), 7.62 (d, *J* = 7.5 Hz, 1H), 7.32 (td, *J* = 7.5, 1.5 Hz, 1H), 7.27–7.24 (m, 1H), 6.73 (dd, *J* = 3.5, 0.5 Hz, 1H), 2.35 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.7, 148.7, 135.3, 130.2, 126.0, 124.2, 123.1, 120.9, 115.2, 107.4, 24.9; HRMS (ESI) *m/z* calcd. for C₁₁H₁₁N₂O₂ [M+H]⁺ 203.0815, found 203.0819.



N-Acetyl-3-methyl-1H-indole-1-carboxamide (1b): The title compound was obtained as a white solid (378 mg) in 35% yield according to the **Method A**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 10.83 (s, 1H), 8.17 (d, $J = 8.0$ Hz, 1H), 7.69 (d, $J = 1.5$ Hz, 1H), 7.56 (d, $J = 7.5$ Hz, 1H), 7.34–7.31 (m, 1H), 7.27 (dt, $J = 7.5, 1.0$ Hz, 1H), 2.32 (s, 3H), 2.24 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.5, 148.5, 135.5, 131.0, 124.4, 122.9, 122.8, 119.1, 116.0, 115.2, 24.8, 9.3; HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 217.0952, found 217.0953.




N-Acetyl-4-methyl-1H-indole-1-carboxamide (1c): The title compound was obtained as a white solid (508 mg) in 47% yield according to the **Method A**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 10.97 (s, 1H), 8.02 (d, $J = 8.5$ Hz, 1H), 7.88 (d, $J = 3.5$ Hz, 1H), 7.21 (d, $J = 8.0$ Hz, 1H), 7.05 (d, $J = 7.5$ Hz, 1H), 6.78 (d, $J = 4.0$ Hz, 1H), 2.48 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.7, 148.7, 135.1, 123.0, 129.8, 125.4, 124.3, 123.4, 112.8, 106.0, 24.9, 18.1; HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 217.0952, found 217.0958.




N-Acetyl-4-(benzyloxy)-1H-indole-1-carboxamide (1d): The title compound was obtained as a white solid (231 mg) in 15% yield according to the **Method A**. ^1H NMR (500 MHz, CDCl_3): δ 8.22 (s, 1H), 7.75 (d, $J = 8.5$ Hz, 1H), 7.48 (d, $J = 7.0$ Hz, 2H), 7.41 (t, $J = 7.5$ Hz, 2H), 7.36–7.32 (m, 2H), 7.29 (t, $J = 7.5$ Hz, 1H), 6.90 (dd, $J = 4.0, 1.0$ Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 5.22 (s, 2H), 2.63 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 172.7, 152.6, 137.6, 136.8, 128.8, 128.2, 127.5, 126.5, 125.4, 122.0, 108.2, 107.2, 105.6, 70.3, 25.0; HRMS (ESI) m/z calcd. for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 309.1234,


found 309.1238.



N-Acetyl-4-bromo-1H-indole-1-carboxamide (1e): The title compound was obtained as a white solid (586 mg) in 65% yield according to the **Method A**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.10 (s, 1H), 8.21 (dt, $J = 8.5, 1.0$ Hz, 1H), 8.02 (d, $J = 4.0$ Hz, 1H), 7.48 (dd, $J = 7.5, 1.0$ Hz, 1H), 7.27 (t, $J = 8.0$ Hz, 1H), 6.69 (dd, $J = 8.5, 1.0$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.6, 148.6, 135.7, 130.4, 127.3, 125.8, 125.6, 114.7, 113.7, 106.4, 24.9; HRMS (ESI) m/z calcd. for $\text{C}_{11}\text{H}_{10}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 280.9920, found 280.9923.




N-Acetyl-5-methyl-1H-indole-1-carboxamide (1f): The title compound was obtained as a white solid (702 mg) in 65% yield according to the **Method A**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 10.93 (s, 1H), 8.07 (d, $J = 8.5$ Hz, 1H), 7.86 (d, $J = 4.0$ Hz, 1H), 7.39 (d, $J = 1.5$ Hz, 1H), 7.14 (dd, $J = 3.5, 1.5$ Hz, 1H), 6.65 (d, $J = 4.0$ Hz, 1H), 2.39 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.6, 148.6, 133.5, 132.0, 130.4, 126.6, 125.5, 120.7, 114.9, 107.2, 24.9, 20.9; HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 217.0952, found 217.0948.




N-Acetyl-5-methoxy-1H-indole-1-carboxamide (1g): The title compound was obtained as a white solid (707 mg) in 61% yield according to the **Method A**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 10.92 (s, 1H), 8.08 (d, $J = 9.5$ Hz, 1H), 7.88 (d, $J = 3.5$ Hz, 1H), 7.13 (d, $J = 2.5$ Hz, 1H), 6.92 (dd, $J = 9.0, 2.5$ Hz, 1H), 6.65 (d, $J = 4.0$ Hz, 1H), 3.79 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.6, 155.7, 148.5, 131.1, 129.9, 126.4, 115.9, 112.9, 107.5, 103.5, 55.3, 24.9; HRMS (ESI) m/z calcd.


for $C_{12}H_{13}N_2O_3$ $[M+H]^+$ 233.0921, found 233.0918.



N-Acetyl-5-(benzyloxy)-1H-indole-1-carboxamide (1h): The title compound was obtained as a white solid (277 mg) in 18% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 10.93 (s, 1H), 8.08 (d, $J = 9.0$ Hz, 1H), 7.88 (d, $J = 4.0$ Hz, 1H), 7.46 (d, $J = 7.5$ Hz, 2H), 7.40 (d, $J = 3.0$ Hz, 2H), 7.33 (d, $J = 7.5$ Hz, 1H), 7.22 (d, $J = 2.5$ Hz, 1H), 7.01 (dd, $J = 9.0, 2.5$ Hz, 1H), 6.65 (d, $J = 3.5$ Hz, 1H), 5.14 (s, 2H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.6, 154.7, 137.2, 131.1, 130.0, 128.3, 127.7, 127.6, 126.5, 125.7, 116.0, 113.6, 107.4, 104.8, 69.6, 24.9; HRMS (ESI) m/z calcd. for $C_{18}H_{17}N_2O_3$ $[M+H]^+$ 309.1234, found 309.1231.




N-Acetyl-5-fluoro-1H-indole-1-carboxamide (1i): The title compound was obtained as a white solid (638 mg) in 58% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.02 (s, 1H), 8.21–8.18 (m, 1H), 7.99 (d, $J = 3.5$ Hz, 1H), 7.43 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.19–7.15 (m, 1H), 6.72 (d, $J = 4.0$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.6, 158.6 (d, $J = 236$ Hz), 148.6, 131.8, 131.2 (d, $J = 10$ Hz), 127.8, 116.4 (d, $J = 10$ Hz), 111.8 (d, $J = 25$ Hz), 107.2 (d, $J = 5$ Hz), 106.3 (d, $J = 24$ Hz), 24.89; HRMS (ESI) m/z calcd. for $C_{11}H_{10}FN_2O_2$ $[M+H]^+$ 221.0721, found 221.0729.




N-Acetyl-5-chloro-1H-indole-1-carboxamide (1j): The title compound was obtained as a white solid (732 mg) in 62% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.04 (s, 1H), 8.18 (d, $J = 8.5$ Hz, 1H), 7.97 (d, $J = 3.5$ Hz, 1H), 7.69 (d, $J = 8.5$ Hz, 1H), 7.34 (dd, $J = 9.0, 2.0$ Hz, 1H), 6.71 (d, $J = 3.5$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.6, 148.5, 133.8,


131.6, 127.6, 127.4, 124.1, 120.3, 116.6, 106.7, 24.9; HRMS (ESI) m/z calcd. for $C_{11}H_{10}ClN_2O_2$ $[M+H]^+$ 237.0425, found 237.0421.



N-Acetyl-5-bromo-1H-indole-1-carboxamide (1k): The title compound was obtained as a white solid (732 mg) in 54% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.04 (s, 1H), 8.13 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 4.0$ Hz, 1H), 7.83 (d, $J = 2.0$ Hz, 1H), 7.45 (dd, $J = 9.0, 2.0$ Hz, 1H), 6.71 (d, $J = 2.35$ Hz, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.6, 148.5, 134.1, 132.1, 127.4, 126.7, 123.4, 117.0, 115.5, 106.6, 24.9; HRMS (ESI) m/z calcd. for $C_{11}H_{10}BrN_2O_2$ $[M+H]^+$ 280.9920, found 280.9924.




Methyl-1-(acetylcarbamoyl)-1H-indole-5-carboxylate (1l): The title compound was obtained as a white solid (494 mg) in 38% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.10 (s, 1H), 8.29–8.27 (m, 2H), 8.01 (d, $J = 4.0$ Hz, 1H), 7.93 (dd, $J = 9.0, 1.0$ Hz, 1H), 6.87 (d, $J = 1.5$ Hz, 1H), 3.87 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 200.1, 176.4, 166.4, 153.0, 143.6, 127.7, 125.0, 124.4, 122.8, 115.2, 107.8, 52.0, 25.0; HRMS (ESI) m/z calcd. for $C_{13}H_{13}N_2O_4$ $[M+H]^+$ 261.0870, found 261.0878.




N-Acetyl-6-methyl-1H-indole-1-carboxamide (1o): The title compound was obtained as a white solid (734 mg) in 68% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 10.94 (s, 1H), 8.04 (s, 1H), 7.81 (d, $J = 4.0$ Hz, 1H), 7.49 (d, $J = 8.0$ Hz, 1H), 7.08 (d, $J = 8.5$ Hz, 1H), 6.67 (d, $J = 4.0$ Hz, 1H), 2.43 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.7, 148.8, 135.7,


133.6, 127.9, 125.3, 124.5, 120.5, 115.4, 107.4, 24.9, 21.5; HRMS (ESI) m/z calcd. for $C_{12}H_{13}N_2O_2$ $[M+H]^+$ 217.0952, found 217.0944.



***N*-Acetyl-6-methoxy-1*H*-indole-1-carboxamide (1p):** The title compound was obtained as a white solid (672 mg) in 58% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.94 (s, 1H), 7.80–7.78 (m, 2H), 7.49 (d, $J = 8.5$ Hz, 1H), 6.90 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.64 (d, $J = 4.5$ Hz, 1H), 3.80 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.7, 157.2, 148.9, 136.3, 124.6, 123.8, 121.4, 112.0, 107.4, 99.6, 55.3, 24.9; HRMS (ESI) m/z calcd. for $C_{12}H_{13}N_2O_3$ $[M+H]^+$ 233.0921, found 233.0928.




***N*-Acetyl-5-fluoro-1*H*-indole-1-carboxamide (1q):** The title compound was obtained as a white solid (572 mg) in 52% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.02 (s, 1H), 7.96–7.93 (m, 2H), 7.64 (dd, $J = 8.5, 5.5$ Hz, 1H), 7.16–7.12 (m, 1H), 6.74 (d, $J = 4.0$ Hz, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.7, 159.9 (d, $J = 236$ Hz), 148.8, 135.4 (d, $J = 13$ Hz), 126.7, 126.5 (d, $J = 4$ Hz), 122.0 (d, $J = 10$ Hz), 111.1 (d, $J = 24$ Hz), 107.2, 102.2 (d, $J = 28$ Hz), 25.0; HRMS (ESI) m/z calcd. for $C_{11}H_{10}FN_2O_2$ $[M+H]^+$ 221.0721, found 221.0729.




***N*-Acetyl-6-chloro-1*H*-indole-1-carboxamide (1r):** The title compound was obtained as a white solid (614 mg) in 52% yield according to the **Method A**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.05 (s, 1H), 8.22 (d, $J = 2.0$ Hz, 1H), 7.95 (d, $J = 4.0$ Hz, 1H), 7.65 (d, $J = 8.5$ Hz, 1H), 7.30 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.76 (dd, $J = 4.0, 1.0$ Hz, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 171.7, 148.6,


135.7, 129.0, 128.8, 127.0, 123.3, 122.3, 115.1, 107.2, 25.0; HRMS (ESI) m/z calcd. for $C_{11}H_{10}ClN_2O_2$ $[M+H]^+$ 237.0425, found 237.0428.



N-Acetyl-5-bromo-1H-indole-1-carboxamide (1s): The title compound was obtained as a white solid (725 mg) in 52% yield according to the **Method A**. 1H NMR (500 MHz, DMSO- d_6): δ 11.05 (s, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 4.0 Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.31 (dd, J = 8.0, 2.0 Hz, 1H), 6.76 (d, J = 3.50 Hz, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.7, 148.6, 135.6, 129.0, 128.8, 126.9, 123.3, 122.3, 115.1, 107.2, 25.0; HRMS (ESI) m/z calcd. for $C_{11}H_{10}BrN_2O_2$ $[M+H]^+$ 280.9920, found 280.9928.




Phenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3a): The title compound was obtained as a white solid (59 mg) in 85% yield according to the **GP1**. 1H NMR (500 MHz, $CDCl_3$): δ 8.00 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.39–7.34 (m, 3H), 7.31 (td, J = 7.5, 1.0 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 9.0 Hz, 2H), 6.51 (s, 1H), 5.68–5.65 (m, 1H), 3.69–3.65 (m, 1H), 3.12–3.06 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.6, 168.4, 150.3, 148.4, 135.8, 133.9, 130.9, 129.7, 126.3, 124.4, 124.3, 121.7, 121.5, 113.2, 100.6, 51.9, 38.1, 24.6; HRMS (ESI) m/z calcd. for $C_{20}H_{17}N_2O_4$ $[M+H]^+$ 349.1183, found 349.1189.




p-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3b): The title compound was obtained as a white solid (62 mg) in 86% yield according to the **GP1**. 1H NMR (500 MHz, $CDCl_3$): δ 8.00 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.37–7.31 (m, 2H), 7.16 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 8.5 Hz, 2H), 6.49 (s, 1H), 5.65–5.62 (m, 1H), 3.67–3.63 (m, 1H), 3.08–3.03 (m,


1H), 2.70 (s, 3H), 2.34 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.6, 168.6, 148.4, 148.0, 136.0, 135.8, 133.9, 130.8, 130.1, 124.3, 124.2, 121.7, 121.1, 113.1, 100.5, 51.8, 38.0, 24.6, 21.0; HRMS (ESI) m/z calcd. for C₂₁H₁₉N₂O₄ [M+H]⁺ 363.1339, found 363.1334.



4-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3c): The title compound was obtained as a white solid (68 mg) in 90% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, *J* = 8.0 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.37–7.29 (m, 2H), 6.95 (dt, *J* = 8.5, 3.0 Hz, 2H), 6.87 (d, *J* = 8.5, 3.0 Hz, 2H), 6.49 (s, 1H), 5.67–5.63 (m, 1H), 3.79 (s, 3H), 3.67–3.62 (m, 1H), 3.09–3.04 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.6, 168.8, 157.6, 148.4, 143.8, 135.9, 133.9, 130.8, 124.4, 124.3, 122.3, 121.7, 114.7, 113.2, 100.5, 55.7, 51.9, 38.1, 24.6; HRMS (ESI) m/z calcd. for C₂₁H₁₉N₂O₅ [M+H]⁺ 379.1288, found 379.1281.




4-Fluorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3d): The title compound was obtained as a white solid (26 mg) in 36% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.38–7.30 (m, 2H), 7.07–6.99 (m, 4H), 6.49 (s, 1H), 5.67–5.64 (m, 1H), 3.66–3.62 (m, 1H), 3.12–3.06 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.7, 168.5, 160.5 (d, *J* = 243 Hz), 148.4, 146.1 (d, *J* = 3 Hz), 135.7, 133.9, 130.9, 124.4 (d, *J* = 18 Hz), 130.0 (d, *J* = 8 Hz), 121.7, 116.5, 116.3, 113.2, 100.5, 51.8, 38.2, 24.6; HRMS (ESI) m/z calcd. for C₂₀H₁₆FN₂O₄ [M+H]⁺ 367.1089, found 367.1092.




4-Chlorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3e): The title compound was obtained as a white solid (40 mg) in 53% yield according to the **GP1**. ¹H NMR


(500 MHz, CDCl₃): δ 8.00 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.38–7.30 (m, 4H), 6.99 (dt, J = 8.5, 2.0 Hz, 2H), 6.49 (s, 1H), 5.67–5.64 (m, 1H), 3.66–3.62 (m, 1H), 3.12–3.07 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.7, 168.2, 148.7, 148.4, 135.7, 133.8, 131.8, 130.8, 129.7, 124.5, 124.3, 122.9, 121.7, 113.2, 100.5, 51.8, 38.2, 24.6; HRMS (ESI) m/z calcd. for C₂₀H₁₆ClN₂O₄ [M+H]⁺ 383.0793, found 383.0790.




4-Bromophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3f): The title compound was obtained as a white solid (55 mg) in 65% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.47 (dt, J = 9.0, 2.5 Hz, 2H), 7.38–7.30 (m, 2H), 6.95 (dt, J = 9.0, 2.5 Hz, 2H), 6.48 (s, 1H), 5.66–5.63 (m, 1H), 3.65–3.61 (m, 1H), 3.12–3.07 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.7, 168.1, 149.3, 148.3, 135.7, 133.8, 132.7, 130.8, 124.5, 124.3, 123.3, 121.7, 119.5, 113.2, 100.5, 51.8, 38.2, 24.6; HRMS (ESI) m/z calcd. for C₂₀H₁₆BrN₂O₄ [M+H]⁺ 427.0288, found 427.0282.




m-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3i): The title compound was obtained as a white solid (59 mg) in 82% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 7.98 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.36–7.28 (m, 2H), 7.23 (d, J = 7.5 Hz, 1H), 7.02 (d, J = 7.5 Hz, 1H), 6.82 (d, J = 10.0 Hz, 1H), 6.79 (s, 1H), 6.49 (s, 1H), 5.65–5.62 (m, 1H), 3.66–3.61 (m, 1H), 3.10–3.05 (m, 1H), 2.69 (s, 3H), 2.32 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.6, 168.5, 150.2, 148.4, 139.9, 135.8, 133.9, 130.8, 129.3, 127.1, 124.4, 124.2, 122.0, 121.7, 118.4, 113.2, 100.5, 51.8, 38.0, 24.6, 21.4; HRMS (ESI) m/z calcd. for C₂₁H₁₉N₂O₄ [M+H]⁺ 363.1339, found 363.1331.



3-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3j): The title compound was obtained as a white solid (64 mg) in 84% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 8.01 (d, $J = 8.0$ Hz, 1H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.37–7.30 (m, 2H), 7.26 (d, $J = 8.5$ Hz, 1H), 6.77 (dd, $J = 8.5, 2.0$ Hz, 1H), 6.64 (dd, $J = 8.0, 1.5$ Hz, 1H), 6.54 (t, $J = 7.0$ Hz, 1H), 6.51 (s, 1H), 5.68–5.65 (m, 1H), 3.74 (s, 3H), 3.67–3.63 (m, 1H), 3.13–3.08 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.7, 168.3, 160.7, 151.2, 148.4, 135.8, 133.9, 130.9, 130.1, 124.4, 124.3, 121.8, 113.7, 113.2, 112.2, 107.5, 100.6, 55.5, 51.9, 38.1, 24.7; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 379.1288, found 379.1284.




3-Chlorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3k): The title compound was obtained as a white solid (44 mg) in 58% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 8.00 (d, $J = 8.0$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.38–7.28 (m, 3H), 7.24–7.21 (m, 1H), 7.08 (t, $J = 7.0$ Hz, 1H), 6.97–6.95 (m, 1H), 6.49 (t, $J = 0.5$ Hz, 1H), 5.66–5.63 (m, 1H), 3.66–3.62 (m, 1H), 3.12–3.07 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.7, 168.0, 150.7, 148.3, 135.6, 134.9, 133.8, 130.8, 130.4, 126.6, 124.5, 124.3, 122.2, 121.8, 119.9, 113.2, 100.5, 51.8, 38.2, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{16}\text{ClN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 383.0793, found 383.0795.




o-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3l): The title compound was obtained as a white solid (55 mg) in 76% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.99 (d, $J = 8.0$ Hz, 1H), 7.58 (d, $J = 7.5$ Hz, 1H), 7.37–7.29 (m, 2H), 7.23–7.18 (m, 2H), 7.15 (td, $J = 7.5, 1.0$ Hz, 1H), 6.96 (dd, $J = 8.0, 1.5$ Hz, 1H), 6.49 (d, $J = 0.5$ Hz, 1H), 5.64–5.61


(m, 1H), 3.71–3.67 (m, 1H), 3.17–3.12 (m, 1H), 2.70 (s, 3H), 2.10 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.2, 149.0, 148.3, 135.9, 133.8, 131.3, 130.8, 130.0, 127.1, 126.5, 124.3, 124.2, 121.8, 121.6, 113.1, 100.4, 51.8, 37.5, 24.6, 16.2; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 363.1339, found 363.1333.



2-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3m): The title compound was obtained as a white solid (61 mg) in 81% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 8.01 (d, $J = 8.0$ Hz, 1H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.37–7.29 (m, 2H), 7.22–7.19 (m, 1H), 7.26 (dd, $J = 8.0, 1.5$ Hz, 1H), 6.96–6.91 (m, 2H), 6.54 (s, 1H), 5.69–5.66 (m, 1H), 3.74 (s, 3H), 3.727–3.68 (m, 1H), 3.16–3.11 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 167.9, 156.0, 148.5, 139.4, 135.9, 134.0, 130.9, 127.4, 124.3, 124.2, 122.7, 121.6, 120.9, 113.2, 112.5, 100.6, 55.8, 51.9, 37.5, 24.7; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 379.1288, found 379.1281.




Methyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3n): The title compound was obtained as a white solid (59 mg) in 72% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.98 (d, $J = 9.0$ Hz, 1H), 7.57 (d, $J = 7.5$ Hz, 1H), 7.36–7.28 (m, 2H), 6.43–6.42 (m, 1H), 5.58–5.55 (m, 1H), 3.72 (s, 3H), 3.46–3.41 (m, 1H), 2.83–2.78 (m, 1H), 2.67 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.5, 170.2, 148.5, 136.1, 133.9, 130.8, 124.3, 124.2, 121.7, 113.2, 100.3, 52.1, 51.9, 37.7, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 287.1026, found 287.1021.




Phenethyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3o): The title

compound was obtained as a white soild (42 mg) in 56% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.98 (d, $J = 8.0$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.36–7.27 (m, 4H), 7.22 (tt, $J = 7.5$, 1.5 Hz, 1H), 7.17 (dd, $J = 8.0$, 1.5 Hz, 2H), 6.27 (d, $J = 1.0$ Hz, 1H), 5.54–5.51 (m, 1H), 4.35–4.32 (m, 2H), 3.44–3.39 (m, 1H), 2.90 (t, $J = 7.0$ Hz, 2H), 2.80–2.75 (m, 1H), 2.66 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.4, 169.6, 148.5, 137.5, 136.0, 133.9, 130.7, 128.9, 128.7, 126.8, 124.2, 124.1, 121.6, 113.1, 100.2, 65.5, 51.8, 37.9, 35.1, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 377.1496, found 377.1491.



(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]


indol-1-yl)acetate (3p): The title compound was obtained as a white soild (48 mg) in 58% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.99 (d, $J = 8.0$ Hz, 1H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.34 (d, $J = 8.5$ Hz, 1H), 7.29 (d, $J = 7.5$ Hz, 1H), 6.42 (s, 1H), 5.55–5.52 (m, 1H), 4.63–4.58 (m, 1H), 3.26–3.22 (m, 1H), 3.10–3.06 (m, 1H), 2.67 (s, 3H), 1.69–1.57 (m, 4H), 1.36–1.28 (m, 2H), 1.00–0.82 (m, 2H), 0.83 (d, $J = 7.0$ Hz, 3H), 0.72 (d, $J = 7.0$ Hz, 3H), 0.62 (d, $J = 8.0$ Hz, 3H), 0.53 (q, $J = 7.0$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.5, 169.1, 148.7, 136.0, 134.0, 130.9, 124.2, 124.1, 121.7, 113.2, 99.9, 75.1, 52.0, 46.9, 40.6, 37.6, 34.2, 31.3, 26.3, 24.6, 23.4, 21.9, 20.8, 16.2; HRMS (ESI) m/z calcd. for $\text{C}_{24}\text{H}_{31}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 411.2278, found 411.2269.



1,3,3-Trimethylbicyclo[2.2.1]heptan-2-yl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]


indol-1-yl)acetate (3q): The title compound was obtained as a white soild (48 mg) in 59% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.98 (d, $J = 8.0$ Hz, 1H), 7.56 (t, $J = 7.0$ Hz, 1H), 7.33 (tt, $J = 7.5$, 1.0 Hz, 1H), 7.29 (tt, $J = 7.5$, 1.5 Hz, 1H), 6.42 (dd, $J = 8.5$, 1.5 Hz, 1H), 5.58–5.55 (m, 1H), 4.40 (dd, $J = 8.0$, 2.0 Hz, 1H), 3.50–3.44 (m, 1H), 2.90–2.83 (m, 1H), 2.66 (d, $J = 1.5$ Hz,

3H), 1.70–1.68 (m, 1H), 1.66–1.53 (m, 3H), 1.45–1.38 (m, 1H), 1.18–1.15 (m, 1H), 1.08 (d, $J = 20.0$ Hz, 3H), 1.04–0.93 (m, 4H), 0.69 (d, $J = 35.5$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.5, 170.2, 148.5, 136.2, 133.9, 130.8, 124.2, 121.6, 113.1, 100.2, 87.2, 52.1, 48.3, 41.4, 39.5, 37.7, 29.8, 26.6, 25.9, 24.6, 20.2, 19.3; HRMS (ESI) m/z calcd. for $\text{C}_{24}\text{H}_{29}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 409.2122, found 409.2129.




5-Methyl-2-(prop-1-en-2-yl)cyclohexyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]


indol-1-yl)acetate (3r): The title compound was obtained as a white solid (30 mg) in 35% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.97 (d, $J = 8.0$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.33 (td, $J = 7.0, 1.0$ Hz, 1H), 7.29 (td, $J = 7.5, 1.0$ Hz, 1H), 6.38 (d, $J = 1.0$ Hz, 1H), 5.53–5.50 (m, 1H), 4.88–4.83 (m, 1H), 4.58 (d, $J = 1.0$ Hz, 2H), 3.36–3.32 (m, 1H), 2.78–2.73 (m, 1H), 2.65 (s, 3H), 2.01–1.95 (m, 1H), 1.91–1.87 (m, 1H), 1.69–1.63 (m, 2H), 1.60 (s, 3H), 1.53–1.29 (m, 2H), 0.99–0.85 (m, 5H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.3, 169.1, 148.5, 145.8, 136.3, 134.0, 130.7, 124.1, 121.5, 113.1, 112.1, 100.2, 77.4, 74.4, 51.9, 50.7, 40.4, 37.8, 34.1, 31.5, 30.3, 24.6, 22.1, 19.6; HRMS (ESI) m/z calcd. for $\text{C}_{24}\text{H}_{29}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 409.2127, found 409.2121.




Phenyl-2-(2-acetyl-9-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3s): The title compound was obtained as a white solid (26 mg) in 36% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.96 (d, $J = 8.0$ Hz, 1H), 7.54 (d, $J = 8.0$ Hz, 1H), 7.38–7.31 (m, 2H), 7.29 (t, $J = 7.5$ Hz, 2H), 7.18 (t, $J = 7.5$ Hz, 1H), 6.88 (d, $J = 7.5$ Hz, 2H), 5.69–5.67 (m, 1H), 3.52–3.48 (m, 1H), 3.33–3.29 (m, 1H), 2.69 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.7, 168.1, 150.3, 148.4, 134.9, 130.8, 130.6, 129.6, 126.2, 124.5, 123.9, 121.4, 119.6, 113.2, 108.9, 51.6, 37.2, 24.6, 8.6; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 363.1339, found 363.1330.



Phenyl-2-(2-acetyl-8-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3t): The title compound was obtained as a white solid (53 mg) in 73% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.82 (d, $J = 8.0$ Hz, 1H), 7.37 (t, $J = 8.0$ Hz, 2H), 7.26–7.23 (m, 2H), 7.10 (d, $J = 7.5$ Hz, 1H), 7.05 (d, $J = 7.5$ Hz, 2H), 6.52 (s, 1H), 5.65–5.62 (m, 1H), 3.69–3.65 (m, 1H), 3.08–3.03 (m, 1H), 2.69 (s, 3H), 2.50 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.5, 150.3, 148.5, 135.2, 133.5, 131.3, 130.5, 129.7, 126.3, 124.7, 124.5, 121.5, 110.6, 99.1, 51.8, 38.2, 24.6, 18.8; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 363.1339, found 363.1334.




Phenyl-2-(2-acetyl-8-(benzyloxy)-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3u): The title compound was obtained as a white solid (53 mg) in 58% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.62 (d, $J = 8.0$ Hz, 1H), 7.47 (d, $J = 7.0$ Hz, 2H), 7.41–7.33 (m, 5H), 7.28–7.22 (m, 2H), 7.05 (d, $J = 9.5$ Hz, 2H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.69 (s, 1H), 5.66–5.64 (m, 1H), 5.21 (s, 2H), 3.65–3.61 (m, 1H), 3.14–3.09 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.4, 152.5, 150.3, 148.6, 137.0, 134.2, 132.1, 129.7, 128.7, 128.1, 127.5, 126.3, 125.5, 124.3, 121.6, 106.5, 106.1, 98.0, 70.3, 51.9, 38.1, 24.7; HRMS (ESI) m/z calcd. for $\text{C}_{27}\text{H}_{23}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 455.1601, found 455.1065.




Phenyl-2-(2-acetyl-7-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3v): The title compound was obtained as a white solid (64 mg) in 88% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.82 (d, $J = 1.0$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.39–7.35 (m, 2H), 7.24 (tt, $J =$


7.5, 1.0 Hz, 1H), 7.13 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.06–7.035 (m, 2H), 6.44 (s, 1H), 5.65–5.62 (m, 1H), 3.68–3.64 (m, 1H), 3.10–3.05 (m, 1H), 2.70 (s, 3H), 2.50 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.7, 168.4, 150.3, 148.5, 135.1, 134.7, 131.6, 131.2, 129.7, 126.3, 125.8, 121.5, 121.3, 113.4, 100.4, 51.9, 38.2, 24.6, 21.8; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 363.1339, found 363.1333.




Phenyl-2-(2-acetyl-7-methoxy-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3w): The title compound was obtained as a white solid (69 mg) in 91% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.86 (d, $J = 9.0$ Hz, 1H), 7.38 (t, $J = 7.5$ Hz, 2H), 7.24 (t, $J = 7.5$ Hz, 1H), 7.05 (dd, $J = 8.5, 1.0$ Hz, 3H), 6.96 (dd, $J = 8.5, 2.0$ Hz, 1H), 6.43 (s, 1H), 5.65–5.62 (m, 1H), 3.86 (s, 3H), 3.69–3.65 (m, 1H), 3.10–3.05 (m, 1H), 2.69 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.4, 157.1, 150.3, 148.2, 136.6, 134.9, 129.7, 126.3, 125.5, 121.5, 113.8, 113.3, 104.4, 100.5, 55.9, 51.8, 38.1, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 379.1288, found 379.1287.




Phenyl-2-(2-acetyl-7-(benzyloxy)-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3x): The title compound was obtained as a white solid (69 mg) in 61% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.88 (d, $J = 8.5$ Hz, 1H), 7.46 (d, $J = 7.5$ Hz, 2H), 7.42–7.32 (m, 5H), 7.24 (t, $J = 7.0$ Hz, 1H), 7.11 (d, $J = 2.0$ Hz, 1H), 7.06–7.02 (m, 3H), 6.42 (d, $J = 1.0$ Hz, 1H), 5.65–5.62 (m, 1H), 5.11 (s, 2H), 3.69–3.64 (m, 1H), 3.09–3.04 (m, 1H), 2.69 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.4, 156.3, 150.3, 148.2, 137.1, 136.7, 134.9, 129.7, 128.7, 128.1, 127.6, 126.3, 125.6, 121.5, 114.1, 113.8, 105.8, 100.5, 70.8, 51.8, 38.1, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{27}\text{H}_{23}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 455.1601, found 455.1068.



Phenyl-2-(2-acetyl-7-fluoro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3y): The title compound was obtained as a white solid (31 mg) in 43% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.95–7.92 (m, 1H), 7.40–7.36 (m, 2H), 7.26–7.23 (m, 2H), 7.08 (td, $J = 8.0, 2.5$ Hz, 1H), 7.05–7.03 (m, 2H), 6.48 (d, $J = 1.0$ Hz, 1H), 5.67–5.64 (m, 1H), 3.69–3.65 (m, 1H), 3.14–3.09 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.6, 168.4, 161.1 (d, $J = 240$ Hz), 150.3, 148.2, 137.6, 134.8 (d, $J = 10$ Hz), 129.7, 127.3, 126.5, 121.5, 114.0 (d, $J = 10$ Hz), 112.5 (d, $J = 26$ Hz), 107.5 (d, $J = 24$ Hz), 100.45 (d, $J = 4$ Hz), 51.9, 37.9, 24.6;; HRMS (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{16}\text{FN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 367.1089, found 367.1082.




Phenyl-2-(2-acetyl-7-chloro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3z): The title compound was obtained as a white solid (30 mg) in 39% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.91 (d, $J = 8.5$ Hz, 1H), 7.56 (d, $J = 1.5$ Hz, 1H), 7.38 (t, $J = 7.5$ Hz, 2H), 7.31 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.24 (t, $J = 7.5$ Hz, 1H), 7.03 (d, $J = 8.5$ Hz, 2H), 6.46 (s, 1H), 5.67–5.64 (m, 1H), 3.69–3.65 (m, 1H), 3.15–3.10 (m, 1H), 2.70 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 170.5, 168.3, 150.2, 148.2, 137.3, 135.0, 130.0, 129.7, 129.2, 126.4, 124.7, 121.5, 121.4, 114.0, 100.0, 51.9, 37.9, 24.6; HRMS (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{16}\text{ClN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 383.0793, found 383.0791.




Phenyl-2-(2-acetyl-7-bromo-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3aa): The title compound was obtained as a white solid (47 mg) in 55% yield according to the **GP1**. ^1H NMR (500 MHz, CDCl_3): δ 7.86 (d, $J = 8.5$ Hz, 1H), 7.73 (d, $J = 1.5$ Hz, 1H), 7.45 (dd, $J = 7.8, 2.0$ Hz, 1H), 7.40–7.36 (m, 2H), 7.24 (t, $J = 7.5$ Hz, 1H), 7.03 (dd, $J = 8.5, 1.0$ Hz, 2H), 6.45 (d, $J = 1.0$ Hz, 1H), 5.67–5.64 (m, 1H), 3.69–3.65 (m, 1H), 3.15–3.10 (m, 1H), 2.69 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3):


δ 170.5, 168.3, 150.2, 148.2, 137.1, 135.5, 129.7, 129.5, 127.4, 126.4, 124.5, 121.5, 117.6, 114.4, 99.8, 51.9, 37.9, 24.6; HRMS (ESI) m/z calcd. for $C_{20}H_{16}BrN_2O_4$ $[M+H]^+$ 427.0288, found 427.0287.



Phenyl-2-(2-acetyl-6-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ab): The title compound was obtained as a white solid (61 mg) in 84% yield according to the **GP1**. 1H NMR (500 MHz, $CDCl_3$): δ 7.83 (d, J = 8.0 Hz, 1H), 7.37–7.34 (m, 3H), 7.24–7.21 (m, 1H), 7.14 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 2H), 6.39 (s, 1H), 5.60–5.57 (m, 1H), 3.65–3.61 (m, 1H), 3.06–3.01 (m, 1H), 2.67 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.6, 168.4, 150.3, 148.3, 135.9, 134.1, 133.9, 129.6, 128.9, 126.3, 125.7, 121.6, 121.5, 112.7, 100.2, 51.8, 38.1, 24.6, 21.7; HRMS (ESI) m/z calcd. for $C_{21}H_{19}N_2O_4$ $[M+H]^+$ 363.1339, found 363.1334.




Phenyl-2-(2-acetyl-6-methoxy-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ac): The title compound was obtained as a white solid (65 mg) in 86% yield according to the **GP1**. 1H NMR (500 MHz, $CDCl_3$): δ 7.50 (d, J = 2.5 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.39–7.35 (m, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.05–7.03 (m, 2H), 6.93 (dd, J = 8.5, 2.0 Hz, 1H), 6.41 (d, J = 1.0 Hz, 1H), 5.63–5.60 (m, 1H), 3.88 (s, 3H), 3.66–3.62 (m, 1H), 3.10–3.05 (m, 1H), 2.69 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.6, 168.4, 157.8, 150.3, 148.5, 134.2, 131.6, 129.6, 127.4, 126.3, 122.2, 121.5, 113.9, 100.3, 96.9, 55.9, 51.9, 38.2, 24.6; HRMS (ESI) m/z calcd. for $C_{21}H_{19}N_2O_5$ $[M+H]^+$ 379.1288, found 379.1281.




Phenyl-2-(2-acetyl-6-fluoro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ad): The title compound was obtained as a white solid (30 mg) in 41% yield according to the **GP1**. 1H NMR


(500 MHz, CDCl₃): δ 7.70 (dd, J = 8.5, 2.5 Hz, 1H), 7.52–7.49 (m, 1H), 7.39–7.35 (m, 2H), 7.24 (tt, J = 7.5, 1.5 Hz, 1H), 7.09–7.03 (m, 3H), 6.48 (d, J = 1.0 Hz, 1H), 5.67–5.64 (m, 1H), 3.68–3.64 (m, 1H), 3.13–3.08 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.6, 168.4, 160.6 (d, J = 241 Hz), 150.3, 148.3, 136.1 (d, J = 4 Hz), 130.8 (d, J = 13 Hz), 130.1, 129.7, 126.4, 122.5 (d, J = 9.5 Hz), 121.5, 112.7 (d, J = 24 Hz), 100.5 (d, J = 28 Hz), 100.3, 51.9, 38.0, 24.7; HRMS (ESI) m/z calcd. for C₂₀H₁₆FN₂O₄ [M+H]⁺ 367.1089, found 367.1081.




Phenyl-2-(2-acetyl-6-chloro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ae): The title compound was obtained as a white solid (28 mg) in 37% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 8.18 (s, 1H), 7.46–7.41 (m, 2H), 7.38 (t, J = 8.0 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 7.5 Hz, 2H), 6.48 (s, 1H), 5.67–5.64 (m, 1H), 3.69–3.65 (m, 1H), 3.14–3.10 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 173.9, 170.6, 148.2, 136.3, 132.7, 131.4, 129.7, 127.6, 126.4, 122.9, 121.5, 117.9, 116.4, 111.1, 100.4, 52.0, 37.9, 24.7; HRMS (ESI) m/z calcd. for C₂₀H₁₆ClN₂O₄ [M+H]⁺ 383.0793, found 383.0799.




Phenyl-2-(2-acetyl-6-bromo-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3af): The title compound was obtained as a white solid (45 mg) in 53% yield according to the **GP1**. ¹H NMR (500 MHz, CDCl₃): δ 8.17 (s, 1H), 7.45–7.41 (m, 2H), 7.38 (t, J = 8.0 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.48 (s, 1H), 5.66–5.63 (m, 1H), 3.69–3.65 (m, 1H), 3.14–3.09 (m, 1H), 2.70 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.5, 168.3, 150.3, 148.2, 136.3, 132.7, 131.4, 129.7, 127.6, 126.4, 122.8, 121.5, 117.9, 116.4, 100.4, 51.9, 37.9, 24.7; HRMS (ESI) m/z calcd. for C₂₀H₁₆BrN₂O₄ [M+H]⁺ 427.0288, found 427.0282.




Phenyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (4a): The title compound was obtained as a yellow solid (40 mg) in 76% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.71 (s, 1H), 7.85 (d, J = 16.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.47–7.41 (m, 3H), 7.29 (t, J = 7.5 Hz, 1H), 7.25–7.22 (m, 3H), 7.04 (t, J = 8.0 Hz, 1H), 7.01 (s, 1H), 6.75 (d, J = 16.0 Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.0, 150.6, 138.3, 136.6, 133.6, 129.5, 127.8, 125.8, 124.4, 121.9, 121.4, 119.9, 114.3, 111.6, 109.5; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 264.1019, found 264.1011.




4-Methoxyphenyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (4b): The title compound was obtained as a yellow solid (33 mg) in 56% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.69 (s, 1H), 7.82 (d, J = 15.5 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 9.0 Hz, 1H), 7.23 (t, J = 8.0 Hz, 1H), 7.13 (dt, J = 9.0, 3.0 Hz, 2H), 7.04 (t, J = 7.0 Hz, 1H), 7.00–6.96 (m, 3H), 6.72 (d, J = 16.0 Hz, 1H), 3.77 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.3, 156.8, 143.9, 138.3, 136.4, 133.6, 127.8, 124.3, 122.6, 121.3, 119.9, 114.39, 114.38, 111.6, 109.3, 55.4; HRMS (ESI) m/z calcd. for $\text{C}_{18}\text{H}_{16}\text{NO}_3$ $[\text{M}+\text{H}]^+$ 294.1125, found 294.1127.




4-Fluorophenyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (4c): The title compound was obtained as a yellow solid (50 mg) in 89% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.71 (s, 1H), 7.85 (d, J = 16.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 7.0 Hz, 4H), 7.23 (t, J = 7.0 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 7.01 (s, 1H), 6.75 (d, J = 16.0 Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.1, 159.6 (d, J = 240 Hz), 146.7 (d, J = 2 Hz), 138.3, 136.8, 133.6, 127.8, 124.4, 123.6 (d, J = 8 Hz), 121.3, 119.9, 116.0 (d, J = 23 Hz), 114.0, 111.6, 109.5; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{FNO}_2$ $[\text{M}+\text{H}]^+$ 282.0925, found 282.0928.



4-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4d): The title compound was obtained as a yellow soild (50 mg) in 84% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.72 (s, 1H), 7.86 (d, $J = 15.5$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.51 (dt, $J = 8.5, 1.5$ Hz, 2H), 7.41 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.27 (dt, $J = 8.5, 1.5$ Hz, 2H), 7.23 (td, $J = 7.0, 1.0$ Hz, 1H), 7.04 (t, $J = 8.0$ Hz, 1H), 7.02 (s, 1H), 6.75 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.9, 149.4, 138.4, 137.1, 133.5, 129.9, 129.4, 127.8, 124.4, 123.9, 121.4, 120.0, 113.9, 111.6, 109.7; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{ClNO}_2$ $[\text{M}+\text{H}]^+$ 298.0629, found 298.0627.




m-Tolyl-(E)-3-(1H-indol-2-yl)acrylate (4g): The title compound was obtained as a yellow soild (34 mg) in 62% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.69 (s, 1H), 7.83 (d, $J = 16.0$ Hz, 1H), 7.60 (d, $J = 7.5$ Hz, 1H), 7.41 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.32 (t, $J = 8.0$ Hz, 1H), 7.25–7.21 (m, 1H), 7.10 (d, $J = 7.5$ Hz, 1H), 7.06–7.00 (m, 4H), 6.73 (d, $J = 16.0$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.0, 150.5, 139.2, 138.3, 136.5, 133.6, 129.2, 127.8, 126.4, 124.3, 122.3, 121.3, 119.9, 118.8, 114.3, 111.6, 109.4, 20.8; HRMS (ESI) m/z calcd. for $\text{C}_{18}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 278.1176, found 278.1172.




3-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4h): The title compound was obtained as a yellow soild (52 mg) in 87% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.72 (s, 1H), 7.85 (d, $J = 16.0$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.48 (d, $J = 8.5$ Hz, 1H), 7.43–7.41 (m, 2H), 7.38–7.36 (m, 1H), 7.25–7.22 (m, 2H), 7.06–7.02 (m, 2H), 6.74 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.7, 151.3, 138.3, 137.0, 133.5, 133.3, 130.9, 127.8, 125.9, 124.4, 122.3,


121.4, 120.9, 119.9, 113.8, 111.6, 109.7; HRMS (ESI) m/z calcd. for $C_{17}H_{13}ClNO_2$ $[M+H]^+$ 298.0629, found 298.0622.



o-Tolyl-(E)-3-(1H-indol-2-yl)acrylate (4i): The title compound was obtained as a yellow solid (33 mg) in 59% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.69 (s, 1H), 7.82 (d, $J = 16.0$ Hz, 1H), 7.59 (d, $J = 7.5$ Hz, 1H), 7.40 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.32 (t, $J = 8.0$ Hz, 1H), 7.24–7.21 (m, 1H), 7.09 (d, $J = 7.5$ Hz, 1H), 7.06–6.99 (m, 4H), 6.73 (d, $J = 16.0$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 164.9, 150.4, 139.0, 138.1, 136.4, 133.4, 129.0, 127.7, 126.2, 124.1, 122.1, 121.2, 119.7, 118.7, 114.1, 111.4, 109.2, 20.6; HRMS (ESI) m/z calcd. for $C_{18}H_{16}NO_2$ $[M+H]^+$ 278.1176, found 278.1173.




2-Methoxyphenyl-(E)-3-(1H-indol-2-yl)acrylate (4j): The title compound was obtained as a yellow solid (28 mg) in 48% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.70 (s, 1H), 7.83 (d, $J = 16.0$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.42 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.27–7.22 (m, 2H), 7.17 (dd, $J = 7.5, 1.5$ Hz, 1H), 7.14 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.07–7.04 (m, 1H), 7.01–6.97 (m, 2H), 6.76 (d, $J = 16.0$ Hz, 1H), 3.78 (s, 3H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 164.5, 151.0, 139.4, 138.3, 136.6, 133.6, 127.9, 126.9, 124.3, 123.0, 121.3, 120.6, 119.9, 114.1, 112.8, 111.6, 109.4, 55.7; HRMS (ESI) m/z calcd. for $C_{18}H_{16}NO_3$ $[M+H]^+$ 294.1125, found 294.1121.




2-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4k): The title compound was obtained as a yellow solid (52 mg) in 86% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.74 (s, 1H), 7.90 (d, $J = 16.0$ Hz, 1H), 7.63–7.60 (m, 2H), 7.46–7.40 (m, 3H), 7.36–7.32 (m, 1H), 7.26–7.22 (m,


1H), 7.07–7.04 (m, 2H), 6.79 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.1, 146.7, 138.4, 137.5, 133.4, 130.1, 128.5, 127.8, 127.5, 126.0, 124.5, 124.4, 121.4, 112.0, 113.2, 111.6, 109.9; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{ClNO}_2$ $[\text{M}+\text{H}]^+$ 298.0629, found 298.0622.



Methyl-(E)-3-(1H-indol-2-yl)acrylate (4l): The title compound was obtained as a yellow solid (30 mg) in 75% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.59 (s, 1H), 7.64 (d, $J = 15.5$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.38 (d, $J = 9.0$ Hz, 1H), 7.20 (t, $J = 7.0$ Hz, 1H), 7.02 (t, $J = 7.5$ Hz, 1H), 6.91 (s, 1H), 6.55 (d, $J = 15.5$ Hz, 1H), 3.73 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.8, 138.1, 134.9, 133.7, 127.8, 124.0, 121.2, 119.8, 115.1, 111.5, 108.6, 51.5; HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{12}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 202.0863, found 202.0863.




Ethyl-(E)-3-(1H-indol-2-yl)acrylate (4m): The title compound was obtained as a yellow solid (27 mg) in 63% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.57 (s, 1H), 7.64 (d, $J = 16.0$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.37 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.21–7.18 (m, 1H), 7.02 (dd, $J = 8.0, 1.0$ Hz, 1H), 6.90 (s, 1H), 6.55 (d, $J = 16.0$ Hz, 1H), 4.19 (q, $J = 76.0$ Hz, 2H), 1.26 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.3, 138.0, 134.7, 133.7, 127.8, 123.9, 121.1, 119.8, 115.6, 111.5, 108.4, 59.9, 14.2; HRMS (ESI) m/z calcd. for $\text{C}_{13}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 216.1019, found 216.1012.




Pentyl-(E)-3-(1H-indol-2-yl)acrylate (4n): The title compound was obtained as a yellow solid (37 mg) in 72% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.57 (s, 1H), 7.62 (d, $J = 16.0$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.37 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.21–7.17 (m, 1H), 7.03–7.00 (m, 1H), 6.91 (s, 1H), 6.55 (d, $J = 16.0$ Hz, 1H), 4.14 (t, $J = 7.0$ Hz, 2H), 1.66–1.63 (m, 2H), 1.35–1.32 (m, 4H), 0.90–0.88 (m, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.4, 138.0, 134.7, 133.7,


127.8, 123.9, 121.1, 119.8, 115.5, 111.5, 108.4, 63.9, 28.0, 27.7, 21.8, 13.9; HRMS (ESI) m/z calcd. for $C_{16}H_{20}NO_2$ $[M+H]^+$ 258.1489, found 258.1485.



Phenethyl-(E)-3-(1H-indol-2-yl)acrylate (4o): The title compound was obtained as a yellow solid (40 mg) in 68% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.59 (s, 1H), 7.62 (d, $J = 16.0$ Hz, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 1H), 7.34–7.29 (m, 4H), 7.25–7.18 (m, 2H), 7.02 (t, $J = 8.0$ Hz, 1H), 6.90 (s, 1H), 6.53 (d, $J = 16.0$ Hz, 1H), 4.37 (t, $J = 7.0$ Hz, 2H), 2.97 (t, $J = 7.0$ Hz, 2H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 166.3, 138.1, 138.1, 134.9, 133.6, 128.8, 128.4, 127.8, 126.4, 124.0, 121.1, 119.8, 115.3, 111.5, 108.6, 64.5, 34.5; HRMS (ESI) m/z calcd. for $C_{19}H_{18}NO_2$ $[M+H]^+$ 292.1332, found 292.1336.




(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl-(E)-3-(1H-indol-2-yl)acrylate (4p): The title compound was obtained as a yellow solid (53 mg) in 55% yield according to the **GP2**. 1H NMR (500 MHz, $CDCl_3$): δ 9.20 (s, 1H), 7.69 (d, $J = 16.0$ Hz, 1H), 7.59 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.34 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.23 (td, $J = 7.0, 1.0$ Hz, 1H), 7.11–7.07 (m, 1H), 6.79 (d, $J = 2.0$ Hz, 1H), 6.35 (d, $J = 16.0$ Hz, 1H), 4.88–4.83 (m, 1H), 2.08–2.05 (m, 1H), 1.96–1.93 (m, 1H), 1.71–1.67 (m, 2H), 1.49–1.44 (m, 2H), 1.11–1.00 (m, 2H), 0.92–0.86 (m, 6H), 0.80–0.79 (m, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 167.0, 138.1, 134.6, 133.7, 128.5, 124.5, 121.5, 120.5, 116.2, 111.4, 108.7, 74.6, 47.3, 41.2, 34.4, 31.5, 26.5, 23.7, 22.1, 20.9, 16.6; HRMS (ESI) m/z calcd. for $C_{21}H_{28}NO_2$ $[M+H]^+$ 326.2115, found 326.2118.




1,3,3-Trimethylbicyclo[2.2.1]heptan-2-yl-(E)-3-(1H-indol-2-yl)acrylate (4q): The title compound


was obtained as a yellow solid (33 mg) in 51% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.60 (s, 1H), 7.65 (d, $J = 16.0$ Hz, 1H), 7.56 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.37 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.21–7.17 (m, 1H), 7.03–7.00 (m, 1H), 6.91 (d, $J = 2.0$ Hz, 1H), 6.59 (d, $J = 16.0$ Hz, 1H), 4.41 (d, $J = 1.5$ Hz, 1H), 1.73–1.63 (m, 4H), 1.48–1.47 (m, 1H), 1.22–1.12 (m, 2H), 1.11 (s, 3H), 1.06 (s, 3H), 0.77 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.8, 138.1, 134.7, 133.7, 127.8, 123.9, 121.1, 119.7, 115.6, 111.5, 108.4, 85.3, 47.9, 47.8, 40.8, 29.5, 26.3, 25.5, 20.0, 19.2; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{26}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 324.1958, found 324.1963.




Methyl-(E)-3-(4-methyl-1H-indol-2-yl)acrylate (4r): The title compound was obtained as a yellow solid (31 mg) in 72% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.57 (s, 1H), 7.64 (d, $J = 16.0$ Hz, 1H), 7.20 (d, $J = 8.0$ Hz, 1H), 7.09 (d, $J = 7.0$ Hz, 1H), 6.93 (s, 1H), 6.81 (d, $J = 7.0$ Hz, 1H), 6.54 (d, $J = 16.0$ Hz, 1H), 3.73 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.8, 137.9, 134.9, 133.1, 130.2, 128.0, 124.2, 119.7, 114.8, 109.1, 107.3, 51.4, 18.4; HRMS (ESI) m/z calcd. for $\text{C}_{13}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 216.1019, found 216.1018.




Phenyl-(E)-3-(4-(benzyloxy)-1H-indol-2-yl)acrylate (4s): The title compound was obtained as a yellow solid (32 mg) in 43% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.71 (s, 1H), 7.82 (d, $J = 16.0$ Hz, 1H), 7.51 (d, $J = 7.50$ Hz, 2H), 7.47–7.40 (m, 4H), 7.34 (t, $J = 7.5$ Hz, 1H), 7.28 (d, $J = 7.50$ Hz, 1H), 7.22–7.21 (m, 2H), 7.14 (t, $J = 8.0$ Hz, 1H), 7.07 (d, $J = 7.0$ Hz, 1H), 7.01 (d, $J = 8.5$ Hz, 1H), 6.72 (d, $J = 16.0$ Hz, 1H), 6.62 (d, $J = 7.5$ Hz, 1H), 5.24 (s, 2H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.1, 152.4, 150.6, 139.7, 137.3, 136.6, 132.4, 129.5, 128.4, 127.8, 127.5, 125.7, 125.5, 121.9, 119.3, 113.6, 107.1, 104.8, 101.0, 69.1; HRMS (ESI) m/z calcd. for $\text{C}_{24}\text{H}_{20}\text{NO}_3$ $[\text{M}+\text{H}]^+$ 370.1438, found 370.1432.




Phenyl-(*E*)-3-(4-bromo-1*H*-indol-2-yl)acrylate (4t): The title compound was obtained as a yellow solid (49 mg) in 72% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 12.08 (s, 1H), 7.89 (d, $J = 16.0$ Hz, 1H), 7.46–7.43 (m, 3H), 7.30–7.28 (m, 2H), 7.24–7.23 (m, 2H), 7.15 (t, $J = 8.0$ Hz, 1H), 6.99 (s, 1H), 6.85 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.8, 150.6, 138.4, 136.0, 134.3, 129.5, 128.4, 125.8, 125.2, 122.6, 121.8, 115.8, 114.3, 111.2, 108.4; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{BrNO}_2$ $[\text{M}+\text{H}]^+$ 342.0124, found 342.0127.




Phenyl-(*E*)-3-(5-methoxy-1*H*-indol-2-yl)acrylate (4u): The title compound was obtained as a yellow solid (38 mg) in 64% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.57 (s, 1H), 7.80 (d, $J = 16.0$ Hz, 1H), 7.45 (t, $J = 7.5$ Hz, 2H), 7.32–7.27 (m, 2H), 7.21 (dt, $J = 7.5, 1.0$ Hz, 2H), 7.07 (d, $J = 2.5$ Hz, 1H), 6.93 (d, $J = 1.5$ Hz, 1H), 6.88 (d, $J = 8.0, 2.5$ Hz, 1H), 6.70 (d, $J = 16.0$ Hz, 1H), 3.76 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.5, 154.2, 151.0, 137.1, 134.3, 134.0, 129.9, 128.6, 126.2, 122.3, 115.9, 114.2, 112.9, 109.4, 102.3, 55.7; HRMS (ESI) m/z calcd. for $\text{C}_{18}\text{H}_{16}\text{NO}_3$ $[\text{M}+\text{H}]^+$ 294.1125, found 294.1120.




Phenyl-(*E*)-3-(5-chloro-1*H*-indol-2-yl)acrylate (4v): The title compound was obtained as a yellow solid (51 mg) in 86% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.90 (s, 1H), 7.83 (d, $J = 16.0$ Hz, 1H), 7.67 (d, $J = 2.0$ Hz, 1H), 7.47–7.42 (m, 3H), 7.29 (t, $J = 7.5$ Hz, 1H), 7.23–7.21 (m, 3H), 7.15 (d, $J = 1.5$ Hz, 1H), 6.78 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.8, 150.5, 136.6, 136.2, 135.0, 129.5, 128.9, 125.8, 124.4, 124.2, 121.8, 120.3, 115.5, 113.2, 108.5; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{ClNO}_2$ $[\text{M}+\text{H}]^+$ 298.0629, found 298.0627.



Phenyl-(*E*)-3-(5-bromo-1*H*-indol-2-yl)acrylate (4w): The title compound was obtained as a yellow soild (56 mg) in 83% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.91 (s, 1H), 7.86–7.81 (m, 2H), 7.52 (t, $J = 8.0$ Hz, 2H), 7.39 (d, $J = 8.5$ Hz, 1H), 7.32 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.28 (t, $J = 7.0$ Hz, 1H), 7.22 (d, $J = 7.5$ Hz, 2H), 6.99 (s, 1H), 6.79 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 164.8, 150.5, 136.8, 136.1, 134.9, 129.6, 129.5, 126.7, 125.8, 123.4, 121.8, 115.5, 113.6, 112.3, 108.4; HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{BrNO}_2$ $[\text{M}+\text{H}]^+$ 342.0124, found 342.0121.




Methyl-(*E*)-2-(3-oxo-3-phenoxyprop-1-en-1-yl)-1*H*-indole-5-carboxylate (4x): The title compound was obtained as a yellow soild (50 mg) in 78% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 12.08 (s, 1H), 8.30 (s, 1H), 7.88–7.83 (m, 2H), 7.50 (d, $J = 8.5$ Hz, 1H), 7.45 (t, $J = 7.5$ Hz, 2H), 7.29 (d, $J = 7.5$ Hz, 1H), 7.22 (dd, $J = 8.5, 1.0$ Hz, 2H), 7.15 (s, 1H), 6.82 (d, $J = 16.0$ Hz, 1H), 3.85 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 166.9, 164.8, 150.5, 140.6, 136.1, 135.3, 129.5, 127.4, 125.8, 124.8, 124.0, 121.8, 121.4, 115.7, 111.6, 110.3, 51.8; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{16}\text{NO}_4$ $[\text{M}+\text{H}]^+$ 322.1074, found 322.1071.




Phenyl-(*E*)-3-(6-methoxy-1*H*-indol-2-yl)acrylate (4y): The title compound was obtained as a yellow soild (32 mg) in 54% yield according to the **GP2**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.57 (s, 1H), 7.80 (d, $J = 16.0$ Hz, 1H), 7.45 (t, $J = 7.5$ Hz, 2H), 7.32–7.27 (m, 2H), 7.22 (dd, $J = 8.5, 1.0$ Hz, 2H), 7.07 (d, $J = 2.5$ Hz, 1H), 6.93 (d, $J = 1.5$ Hz, 1H), 6.87 (dd, $J = 9.0, 2.5$ Hz, 1H), 6.70 (d, $J = 16.0$ Hz, 1H), 3.76 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 165.1, 153.8, 150.6, 136.7, 133.9, 133.6,


129.5, 128.2, 125.7, 121.9, 115.4, 113.7, 112.4, 109.0, 101.9, 55.3; HRMS (ESI) m/z calcd. for $C_{18}H_{16}NO_3$ $[M+H]^+$ 294.1125, found 294.1127.



Phenyl-(*E*)-3-(6-fluoro-1*H*-indol-2-yl)acrylate (4z): The title compound was obtained as a yellow solid (48 mg) in 86% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.84 (s, 1H), 7.83 (d, $J = 16.0$ Hz, 1H), 7.64–7.62 (m, 1H), 7.46 (t, $J = 8.0$ Hz, 2H), 7.29 (t, $J = 7.5$ Hz, 1H), 7.22 (dd, $J = 7.5, 1.0$ Hz, 2H), 7.19 (dd, $J = 10.0, 2.0$ Hz, 1H), 7.03 (d, $J = 1.5$ Hz, 1H), 6.95–6.91 (m, 1H), 6.75 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 165.0, 160.5 (d, $J = 238$ Hz), 150.6, 138.4 (d, $J = 13$ Hz), 136.3, 134.4 (d, $J = 4$ Hz), 129.5, 125.8, 124.7, 122.8 (d, $J = 10$ Hz), 121.9, 114.3, 109.6, 108.9 (d, $J = 25$ Hz), 97.4 (d, $J = 26$ Hz); HRMS (ESI) m/z calcd. for $C_{17}H_{13}FNO_2$ $[M+H]^+$ 282.0925, found 282.0924.




Phenyl-(*E*)-3-(6-chloro-1*H*-indol-2-yl)acrylate (4aa): The title compound was obtained as a yellow solid (53 mg) in 88% yield according to the **GP2**. 1H NMR (500 MHz, $DMSO-d_6$): δ 11.86 (s, 1H), 7.85 (d, $J = 16.0$ Hz, 1H), 7.59–7.56 (m, 2H), 7.45 (t, $J = 8.0$ Hz, 2H), 7.29 (t, $J = 7.5$ Hz, 1H), 7.22 (d, $J = 8.0$ Hz, 2H), 7.17 (dd, $J = 8.5, 1.5$ Hz, 1H), 7.03 (s, 1H), 6.78 (d, $J = 16.0$ Hz, 1H); ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 164.9, 150.5, 138.9, 136.2, 134.5, 129.5, 126.8, 125.8, 123.1, 123.0, 121.8, 117.0, 115.2, 114.0, 109.2; HRMS (ESI) m/z calcd. for $C_{17}H_{13}ClNO_2$ $[M+H]^+$ 298.0629, found 298.0621.




3-Benzamido-3-(1*H*-indol-2-yl)propanoic acid (5a): The title compound was obtained as a white solid (32 mg) in 53% yield according to the **GP3** and (41 mg) in 67% yield according to the **GP4**. 1H


NMR (500 MHz, DMSO- d_6): δ 12.36 (s, 1H), 10.96 (s, 1H), 8.84 (d, J = 8.0 Hz, 1H), 7.90–7.89 (m, 2H), 7.54 (t, J = 7.0 Hz, 1H), 7.49–7.44 (m, 3H), 7.33 (d, J = 8.5 Hz, 1H), 7.04–7.01 (m, 1H), 6.96–6.93 (m, 1H), 6.21 (s, 1H), 5.72–5.67 (m, 1H), 3.02–2.92 (m, 2H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.8, 165.7, 139.9, 136.0, 134.3, 131.2, 128.2, 127.6, 127.4, 120.7, 119.6, 118.8, 111.2, 98.1, 44.5; HRMS (ESI) m/z calcd. for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 309.1234, found 309.1238.




3-Benzamido-3-(4-methyl-1H-indol-2-yl)propanoic acid (5b): The title compound was obtained as a white solid (30 mg) in 48% yield according to the **GP3** and (41 mg) in 63% yield according to the **GP4**. ^1H NMR (500 MHz, DMSO- d_6): δ 12.35 (s, 1H), 10.95 (s, 1H), 8.83 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.54 (t, J = 7.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 6.93 (t, J = 7.0 Hz, 1H), 6.74 (d, J = 7.0 Hz, 1H), 6.33 (d, J = 2.0 Hz, 1H), 5.72–5.67 (m, 1H), 3.03–2.92 (m, 2H), 2.41 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.8, 165.7, 139.2, 135.7, 134.3, 131.3, 128.3, 128.2, 127.5, 127.4, 120.9, 118.9, 108.9, 96.6, 44.5, 18.6; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 323.1390, found 323.1392.




3-Benzamido-3-(5-methyl-1H-indol-2-yl)propanoic acid (5c): The title compound was obtained as a white solid (32 mg) in 50% yield according to the **GP3** and (42 mg) in 65% yield according to the **GP4**. ^1H NMR (500 MHz, DMSO- d_6): δ 12.34 (s, 1H), 10.82 (s, 1H), 8.83 (d, J = 8.0 Hz, 1H), 7.90–7.89 (m, 2H), 7.54 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 6.85 (dd, J = 8.5, 1.0 Hz, 1H), 6.22 (s, 1H), 5.70–5.66 (m, 1H), 3.01–2.91 (m, 2H), 2.33 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.9, 165.7, 139.9, 134.4, 134.3, 131.3, 128.2, 127.9, 127.5, 127.2, 122.3, 119.3, 110.9, 97.6, 44.5, 21.2; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 323.1390, found 323.1396.



3-Benzamido-3-(5-methoxy-1H-indol-2-yl)propanoic acid (5d): The title compound was obtained as a white solid (38 mg) in 56% yield according to the **GP3** and (49 mg) in 73% yield according to the **GP4**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 12.34 (s, 1H), 10.78 (s, 1H), 8.83 (d, $J = 8.5$ Hz, 1H), 7.90–7.88 (m, 2H), 7.54 (t, $J = 7.5$ Hz, 1H), 7.48 (t, $J = 7.5$ Hz, 2H), 7.21 (d, $J = 8.5$ Hz, 1H), 6.96 (d, $J = 7.5$ Hz, 1H), 6.67 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.23 (d, $J = 2.0$ Hz, 1H), 5.68–5.64 (m, 1H), 3.71 (s, 3H), 3.00–2.90 (m, 2H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.8, 165.7, 153.3, 140.5, 134.3, 131.3, 131.1, 128.2, 128.0, 127.4, 111.8, 110.7, 101.6, 99.5, 98.0, 55.3, 44.5; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 339.1339, found 339.1345.




3-Benzamido-3-(6-methyl-1H-indol-2-yl)propanoic acid (5g): The title compound was obtained as a white solid (29 mg) in 46% yield according to the **GP3** and (44 mg) in 68% yield according to the **GP4**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 12.33 (s, 1H), 10.80 (s, 1H), 9.16 (s, 1H), 8.82 (d, $J = 8.5$ Hz, 1H), 7.88 (d, $J = 7.0$ Hz, 2H), 7.54 (t, $J = 7.5$ Hz, 1H), 7.48 (t, $J = 7.5$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.12 (s, 1H), 6.24 (s, 1H), 5.70–5.65 (m, 1H), 3.01–2.90 (m, 2H), 2.36 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 171.8, 165.7, 139.2, 136.5, 134.3, 131.3, 129.7, 128.2, 127.5, 125.5, 120.6, 119.4, 111.1, 97.9, 44.5, 21.5; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 323.1390, found 323.1391.




3-Benzamido-3-(6-methoxy-1H-indol-2-yl)propanoic acid (5h): The title compound was obtained as a white solid (39 mg) in 58% yield according to the **GP3** and (51 mg) in 76% yield according to the **GP4**. ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 12.51 (s, 0.7H), 10.81 (s, 1H), 8.96 (d, $J = 8.0$ Hz, 1H), 7.90 (d, $J = 7.0$ Hz, 2H), 7.53 (t, $J = 7.5$ Hz, 1H), 7.46 (t, $J = 8.0$ Hz, 2H), 7.30 (d, $J = 9.0$ Hz, 1H), 6.85 (d, $J = 1.5$ Hz, 1H), 6.59 (d, $J = 8.0$ Hz, 1H), 6.20 (s, 1H), 5.67–5.63 (m, 1H), 3.72 (s, 3H),

3.04–2.79 (m, 2H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.9, 165.7, 155.3, 138.6, 136.8, 134.4, 131.3, 128.2, 127.5, 121.8, 120.2, 108.9, 98.0, 94.6, 55.2, 44.5; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 339.1339, found 339.1345.




3-((Tert-butoxycarbonyl)amino)-3-(5-chloro-1H-indol-2-yl)propanoic acid (5i): The title compound was obtained as a white solid (18 mg) in 27% yield according to the **GP5** and (32 mg) in 48% yield according to the **GP6**. ^1H NMR (500 MHz, DMSO- d_6): δ 12.33 (s, 1H), 11.12 (s, 1H), 7.50 (d, $J = 2.0$ Hz, 1H), 7.36 (d, $J = 8.5$ Hz, 1H), 7.33 (d, $J = 8.5$ Hz, 1H), 7.01 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.22 (d, $J = 2.0$ Hz, 1H), 5.12–5.07 (m, 1H), 2.82–2.70 (m, 2H), 1.39 (s, 9H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.6, 154.9, 142.5, 134.4, 128.9, 123.3, 120.6, 118.8, 112.6, 97.7, 78.1, 45.6, 28.2; HRMS (ESI) m/z calcd. for $\text{C}_{16}\text{H}_{20}\text{ClN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 339.1106, found 339.1109.



3-((Tert-butoxycarbonyl)amino)-3-(5-bromo-1H-indol-2-yl)propanoic acid (5j): The title compound was obtained as a white solid (32 mg) in 43% yield according to the **GP4** and (41 mg) in 54% yield according to the **GP3**. ^1H NMR (500 MHz, DMSO- d_6): δ 12.27 (s, 1H), 11.13 (s, 1H), 7.64 (d, $J = 1.5$ Hz, 1H), 7.36 (d, $J = 8.5$ Hz, 1H), 7.28 (d, $J = 8.5$ Hz, 1H), 7.14 (d, $J = 7.0$ Hz, 1H), 6.22 (d, $J = 2.0$ Hz, 1H), 5.11–5.07 (m, 1H), 2.82–2.69 (m, 2H), 1.38 (s, 9H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.6, 154.9, 142.3, 134.6, 129.6, 123.1, 121.9, 113.2, 111.3, 97.6, 78.1, 45.5, 28.2; HRMS (ESI) m/z calcd. for $\text{C}_{16}\text{H}_{20}\text{BrN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ 383.0601, found 383.0612.

4. Synthetic Applications


4.1 Hydrolysis of 3a



A reaction tube (10 mL) with magnetic stir bar was charged with phenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate **3a** (35 mg, 0.10 mmol), LiOH (6 mg, 0.25 mmol), H₂O (1.0 mL), and THF (1.0 mL). The reaction was allowed to stir at 45°C oil bath for 2h. After cooling to room temperature, the reaction was poured in 10 mL 0.5 M HCl and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with brine and dried over sodium sulphate. The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (CH₂Cl₂/MeOH) to afford the desired products **6** as white solide (18 mg) in 78 % yield.

2-(3-Oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetic acid (6): ¹H NMR (500 MHz, DMSO-*d*₆): δ 12.99 (s, 1H), 8.44 (s, 1H), 7.80 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 7.5 Hz, 1H), 7.23 (t, *J* = 7.0 Hz, 1H), 7.18 (t, *J* = 7.0 Hz, 1H), 6.42 (s, 1H), 5.00 (t, *J* = 6.0 Hz, 1H), 2.73 (d, *J* = 5.5 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 179.2, 152.3, 141.8, 133.1, 129.5, 122.4, 122.0, 121.1, 111.5, 96.9, 75.1, 49.2; HRMS (ESI) *m/z* calcd. for C₁₂H₁₁N₂O₃ [M+H]⁺ 231.0764, found 231.0769.

4.2 Hydrolysis of 4aa




A reaction tube (10 mL) with magnetic stir bar was charged with phenyl-(*E*)-3-(6-chloro-1H-indol-2-yl)acrylate (**4aa**) (30 mg, 0.10 mmol), LiOH (6 mg, 0.25 mmol), H₂O (1.0 mL), and THF (1.0 mL). The reaction was allowed to stir at 25 °C oil bath for 2 h. After cooling to room temperature, the reaction was poured in 10 mL 0.5 M HCl and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with brine and dried over sodium sulphate. The solvent was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (CH₂Cl₂/MeOH) to afford the desired products **7** as yellow solide (19 mg) in 85 % yield.

(E)-3-(6-Chloro-1H-indol-2-yl)acrylic acid (7): ^1H NMR (500 MHz, DMSO- d_6): δ 11.83 (s, 1H), 7.54–7.46 (m, 3H), 7.13 (s, 1H), 6.80 (s, 1H), 6.53 (d, J = 14.5 Hz, 1H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 168.4, 138.6, 135.5, 132.0, 127.0, 122.5, 122.4, 120.8, 115.9, 113.9, 106.5; HRMS (ESI) m/z calcd. for $\text{C}_{11}\text{H}_9\text{ClNO}_2$ $[\text{M}+\text{H}]^+$ 222.0316, found 222.0317.

5. Mechanism Study

5.1 Effect of NH on C-H Bond Activation


5.1.1 Preparation of 8



A reaction tube (20 mL) with magnetic stir bar was charged with *N*-acetyl-1*H*-indole-1-carboxamide **1a** (101 mg, 0.50 mmol), MeI (212 mg, 1.5 mmol), Cs_2CO_3 (326 mg, 1.0 mmol) and CH_3CN (8.0 mL). The reaction was allowed to stir at 60 °C oil bath for 6 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **8** as white solid (67 mg) in 62 % yield.


***N*-Acetyl-*N*-methyl-1*H*-indole-1-carboxamide (8):** ^1H NMR (500 MHz, DMSO- d_6): δ 8.01 (dd, J = 8.0, 0.5 Hz, 1H), 7.65–7.64 (m, 2H), 7.36 (td, J = 7.5, 1.0 Hz, 1H), 7.29 (td, J = 7.5, 1.0 Hz, 1H), 6.76 (dd, J = 3.5, 0.5 Hz, 1H), 3.21 (s, 3H), 2.12 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ 171.6, 153.7, 134.9, 130.5, 127.4, 124.6, 123.6, 121.2, 114.6, 108.6, 34.1, 23.2; HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 217.0972, found 217.0968.

5.1.2 Effect of NH on C-H bond activation



A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl-*N*-methyl-1*H*-indole-1-carboxamide **12** (44 mg, 0.20 mmol), phenyl acrylate **2a** (89 mg, 0.60 mmol), [Cp*RhCl₂]₂ (6 mg, 0.010 mmol), AgSbF₆ (21 mg, 0.060 mmol), CsOAc (57 mg, 0.30 mmol) and MeOH (1.0 mL). The reaction was allowed to stir at 80 °C oil bath for 12 h. However, no **4a** was detected.

5.2 Preparation of Rhodacycle **9**




A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl-1*H*-indole-1-carboxamide **1a** (30 mg, 0.15 mmol), [Cp*RhCl₂]₂ (30 mg, 0.050 mmol), NaOAc (25 mg, 0.30 mmol) and TFE (5.0 mL). The reaction was allowed to stir at 60 °C oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and dissolved in dichloromethane (15 mL). Then the mixture was filtered and evaporated to dryness. The solid obtained was washed with ether to remove excess **1a**. The solvent was then removed under vacuum. Analytically pure **9** (37 mg, 85% yield) was obtained by recrystallization using dichloromethane and ethyl acetate.

5-Membered rhodacycle 9: ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.20 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 7.0 Hz, 1H), 7.26 (td, *J* = 7.5, 1.5 Hz, 1H), 7.21 (td, *J* = 8.0, 1.5 Hz, 1H), 6.35 (s, 1H), 2.84 (s, 3H), 0.90 (s, 15H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 179.0, 161.3, 140.8, 134.6, 124.0, 122.6, 121.4, 113.5, 99.6, 82.6, 28.7, 8.5; HRMS (ESI) *m/z* calcd. for C₂₁H₂₄N₂O₂Rh [M+H]⁺ 439.0887, found 439.0885.


The infrared spectroscopy of intermediate **9** was undertaken and the result was as following figure S1. The N–H stretching signals of amide are unfound, which indicated that the hydrogen was substituted. The C–H stretching signals can be assigned primarily to CH₃– (2907 and 2849 cm⁻¹). A central region contains peaks at 1673 and 1623 cm⁻¹ which is assigned to the C=O

stretch.


Figure S1 infrared spectroscopy of intermediate **9**



5.3 9 Leading to Products **3a** and **4a**




A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl-1*H*-indole-1-carboxamide **1a** (40 mg, 0.20 mmol), phenyl acrylate **2a** (89 mg, 0.60 mmol), **9** (9 mg, 0.020 mmol), AgSbF₆ (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), KHSO₄ (41 mg, 0.30 mmol) and TFE (1.0 mL). The reaction was allowed to stir at 60 °C oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **3a** in 88% yied.




A reaction tube (10 mL) with magnetic stir bar was charged with *N*-acetyl-1*H*-indole-1-carboxamide **1a** (40 mg, 0.20 mmol), phenyl acrylate **2a** (89 mg, 0.60 mmol), **9** (9 mg, 0.020 mmol), AgSbF₆ (21 mg, 0.060 mmol), CsOAc (57 mg, 0.30 mmol) and MeOH (1.0 mL). The reaction was allowed to stir at 80 °C oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **4a** in 81% yield.

5.4 Effect of AgSbF₆ on C-H Bond Activation



A reaction tube (10 mL) with magnetic stir bar was charged with **9** (9 mg, 0.020 mmol), phenyl acrylate **2a** (9 mg, 0.060 mmol), AgSbF₆ (21 mg, 0.060 mmol), NaOAc (5 mg, 0.060 mmol), KHSO₄ (8 mg, 0.060 mmol) and TFE (0.50 mL). The reaction was allowed to stir at 60 °C oil bath for 2 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **3a** in 91% yield.




A reaction tube (10 mL) with magnetic stir bar was charged with **9** (9 mg, 0.020 mmol), phenyl acrylate **2a** (9 mg, 0.060 mmol), NaOAc (5 mg, 0.060 mmol), KHSO₄ (8 mg, 0.060 mmol) and TFE (0.50 mL). The reaction was allowed to stir at 60 °C oil bath for 2 h. After cooling to room

temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **3a** in 13% yield.


5.5 KIE Experiments

5.5.1 Reaction procedure for the preparation of deuterium labeled compounds³



2-Deutero-N-acetyl-1H-indole-1-carboxamide (1a-d): a white solid. 55% yield. ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.00 (s, 1H), 8.21 (d, *J* = 9.0 Hz, 1H), 7.91 (d, *J* = 4.0 Hz, 0.05H), 7.62 (d, *J* = 7.5 Hz, 1H), 7.32 (td, *J* = 7.5, 1.5 Hz, 1H), 7.25 (td, *J* = 7.5, 1.5 Hz, 1H), 6.73 (s, 1H), 2.36 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.8, 148.8, 135.3, 130.2, 126.0 (t, *J* = 28.1 Hz), 124.2, 123.1, 121.0, 115.3, 107.3, 25.0; HRMS (ESI) *m/z* calcd. for C₁₁H₁₀DN₂O₂ [M+H]⁺ 204.0878, found 204.0875.

5.5.2 kinetic isotope effect experiment



A reaction tube (10 mL) with magnetic stir bar was charged with **1a** or **1a-d** (40 mg, 0.20 mmol), phenyl acrylate **2a** (89 mg, 0.60 mmol), [Cp^{*}RhCl₂]₂ (3 mg, 0.005 mmol), AgSbF₆ (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), KHSO₄ (41 mg, 0.30 mmol) and TFE (2.0 mL). The mixture was then stirred at room temperature for 10mins before heating to 60 °C. Base on the above procedure, the reaction was heated to 60 °C for 5 min, 15 min, 30 min, 40 min, 50 min, 60 min

separately. The aliquots was got from the reaction and diluted with solvent. The sample was then analyzed by Analytical high performance liquid chromatography (HPLC). HPLC was performed on Agilent 1200 compact chromatograph equipped with Eclipse Plus C18 column (Agilent, 5 μ m, 4.6 \times 150 mm).

Table S3. Yield of **3a** using **1a** or **1a-d** as starting material^a.

Entry	Time (min)	Amount of 3a (mmol)	
		3a ^b	3a ^c
1	5	0.01005	0.01092
2	15	0.03218	0.02561
3	30	0.04739	0.03633
4	40	0.06952	0.04670
5	50	0.07868	0.05362
6	60	0.09182	0.07177

^a HPLC yield. ^b **1a** using as starting material. ^c **1a-d** using as starting material.





Figure S2. Rate profile at initial stage within 60 min.

$$\text{KIE} = K_H/K_D = 1.44$$

5.6 Deuterium Labeling Experiment



A reaction tube (10 mL) with magnetic stir bar was charged with **1a** (40 mg, 0.20 mmol), $[\text{Cp}^*\text{RhCl}_2]_2$ (6 mg, 0.010 mmol), AgSbF_6 (21 mg, 0.060 mmol), NaOAc (25 mg, 0.30 mmol), D_2O (0.50 mL) and DCE (2.0 mL). The reaction was allowed to stir at $60\text{ }^\circ\text{C}$ oil bath for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove the solvent and directly loaded onto silica gel for flash column chromatography (PET/EtOAc) to afford the desired products **10**.


2,7-Dideutero-N-acetyl-1H-indole-1-carboxamide (10): a white solid. 85% yield. ^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ 10.99 (s, 1H), 8.20 (d, $J = 8.0$ Hz, 0.36 H), 7.90 (d, $J = 3.5$ Hz, 0.14 H), 7.61 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.34–7.30 (m, 1H), 7.25 (t, $J = 7.5$ Hz, 1H), 6.73 (s, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$): δ 171.8, 148.8, 135.2 (t, $J = 8.8$ Hz), 130.2, 125.9 (t, $J = 26.2$ Hz), 124.2 (d, $J = 14.0$ Hz), 123.1, 121.0, 115.0 (t, $J = 27.0$ Hz), 107.3 (d, $J = 22.5$ Hz), 25.0; HRMS (ESI) m/z calcd. for $\text{C}_{11}\text{H}_9\text{D}_2\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 205.0941, found 205.0938.

5.7 The Synthesis of Ortho Alkenylated Complex E

The following three ways were tried and all failed to afford the ortho alkenylated complex **E**. We suppose that the ortho alkenylated complex **E** is unstably and unavailable.


Firstly, we tried to change the reaction conditions to obtain the complex **E**. Based on the previous research reports,⁴ we attempt the following conditions and failed to obtain the ortho alkenylated complex **E**.

Table S4. Optimization of Reaction Conditions of E^a




entry	solvent	additive	T (°C)	yield (%) ^b
1	TFE	AgSbF ₆ /NaOAc	45	<5
2	TFE	AgSbF ₆ /NaOAc	25	<5
3	DCE	AgSbF ₆ /NaOAc	45	<5
4	MeOH	AgSbF ₆ /NaOAc	45	<5
5	MeCN	AgSbF ₆ /NaOAc	45	<5
6	THF	AgSbF ₆ /NaOAc	45	<5

^aReaction conditions: **1a** (0.2 mmol), **2n** (0.6 mmol), [Cp^{*}RhCl₂]₂ (0.01 mmol), AgSbF₆ (0.06 mmol), NaOAc (0.3 mmol), and solvent (1 mL). ^bIsolated yield.



A reaction tube (10 mL) with magnetic stir bar was charged with indole **4j** (1.0 mmol, 1.0 equiv.), 1,1'-carbonyldiimidazole (CDI, 1.5 mmol, 1.5 equiv.) and 4-dimethylaminepyridine (DMAP, 5.0 mol %). Then 5 mL anhydrous acetonitrile was added to the reaction tube. The reaction system was stirred at 120 °C oil bath for 10 h. After cooling to room temperature, ammonium hydroxide (1.5 mmol) was added and then the reaction was stirred at 60°C oil bath for another 6 h. However, no product **E** was detected.



A reaction tube (10 mL) with magnetic stir bar was charged with 1*H*-indol-2-ylcarboxaldehyde (1.0 mmol, 1.0 equiv.), 1,1'-carbonyldiimidazole (CDI, 1.5 mmol, 1.5 equiv.) and 4-dimethylaminepyridine (DMAP, 5.0 mol %). Then 5 mL anhydrous acetonitrile was added to the reaction tube. The reaction system was stirred at 120 °C oil bath for 10 h. After cooling to room temperature, ammonium hydroxide (1.5 mmol) was added and then the reaction was stirred at 60 °C oil bath for another 6h. However, no product **E** was detected.


6. References

- (1) Q. Xiao, Q. He, J. Li and J. Wang, *Org. Lett.*, 2015, **17**, 6090.
- (2) (a) K. N. Parida and J. N. Moorthy, *J. Org. Chem.*, 2015, **80**, 8354; (b) P. Zhou, B. Hu, J. Yang, L. Li, K. Rao, D. Zhu and F. Yu, *Eur. J. Org. Chem.*, 2017, **2017**, 7256.
- (3) (a) J. J. Maresh, L. Giddings, A. Friedrich, E. A. Loris, S. Panjekar, B. L. Trout, J. Stöckigt, B. Peters and S. E. O'Connor, *J. Am. Chem. Soc.* 2008, **130**, 710; (b) W. Kong, X. Chen, M. Wang, H.-X. Dai and J. Yu, *Org. Lett.*, 2017, **20**, 284.
- (4) J. Zhang, H. Xie, H. Zhu, S. Zhang, M. Reddy Lonka and H. Zou, *ACS Catal.*, 2019, **9**, 10233.


7. NMR Spectra

N-Acetyl-1*H*-indole-1-carboxamide (**1a**)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




N-Acetyl-4-methyl-1*H*-indole-1-carboxamide (**1b**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-4-methyl-1*H*-indole-1-carboxamide (1c)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-4-(benzyloxy)-1*H*-indole-1-carboxamide (**1d**)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




N-Acetyl-4-bromo-1*H*-indole-1-carboxamide (**1e**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-methyl-1*H*-indole-1-carboxamide (1f)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-methoxy-1*H*-indole-1-carboxamide (**1g**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-(benzyloxy)-1*H*-indole-1-carboxamide (**1h**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-fluoro-1*H*-indole-1-carboxamide (**1i**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




***N*-Acetyl-5-chloro-1*H*-indole-1-carboxamide (**1j**)**

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




***N*-Acetyl-5-bromo-1*H*-indole-1-carboxamide (1k)**

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Methyl-1-(acetylcabamoyl)-1H-indole-5-carboxylate (1I)

¹H NMR, 500 MHz, DMSO-d₆




¹³C NMR, 125 MHz, DMSO-d₆




N-Acetyl-6-methyl-1*H*-indole-1-carboxamide (1o)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-6-methoxy-1*H*-indole-1-carboxamide (**1p**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-fluoro-1*H*-indole-1-carboxamide (1q)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-6-chloro-1*H*-indole-1-carboxamide (**1r**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




N-Acetyl-5-bromo-1*H*-indole-1-carboxamide (**1s**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3a)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




p-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[5,4-b]indol-1-yl)acetate (3b)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




4-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3c)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




4-Fluorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3d)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




4-Chlorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3e)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




4-Bromophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3f)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




m-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3i)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




3-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3j)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




3-Chlorophenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3k)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




o-Tolyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3j)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




2-Methoxyphenyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3m)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Methyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3n)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenethyl-2-(2-acetyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3o)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




(1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl-2-(2-acetyl-3-oxo-2,3-dihydro-1*H*-imidazo[1,5-*a*]indol-1-yl)acetate (3p)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




1,3,3-Trimethylbicyclo[2.2.1]heptan-2-yl-2-(2-acetyl-3-oxo-2,3-dihydro-1*H*-imidazo[1,5-*a*]indol-1-yl)acetate (3q)

¹H NMR, 500 MHz, CDCl₃





¹³C NMR, 125 MHz, CDCl₃





5-Methyl-2-(prop-1-en-2-yl)cyclohexyl-2-(2-acetyl-3-oxo-2,3-dihydro-1*H*-imidazo[1,5-*a*]indol-1-yl)acetate (3r)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-9-methyl-3-oxo-2,3-dihydro-1*H*-imidazo[1,5-*a*]indol-1-yl)acetate (3s)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-8-methyl-3-oxo-2,3-dihydro-1*H*-imidazo[1,5-*a*]indol-1-yl)acetate (3t)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-8-(benzyloxy)-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3u)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-7-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3v)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-7-methoxy-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3w)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-7-(benzyloxy)-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3x)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




Phenyl-2-(2-acetyl-7-fluoro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3y)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-7-chloro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3z)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-7-bromo-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3aa)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-6-methyl-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ab)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-6-methoxy-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ac)

^1H NMR, 500 MHz, CDCl_3





^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-6-fluoro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ad)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-6-chloro-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3ae)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-2-(2-acetyl-6-bromo-3-oxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-yl)acetate (3af)

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




Phenyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (4a)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




4-Methoxyphenyl-(E)-3-(1H-indol-2-yl)acrylate (4b)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




4-Fluorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4c)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




4-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4d)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




***m*-Tolyl (*E*)-3-(1*H*-indol-2-yl)acrylate (4g)**

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




3-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4h)

¹H NMR, 500 MHz, DMSO-d₆




¹³C NMR, 125 MHz, DMSO-d₆




o-Tolyl-(E)-3-(1H-indol-2-yl)acrylate (4i)

¹H NMR, 500 MHz, DMSO-d₆




¹³C NMR, 125 MHz, DMSO-d₆




2-Methoxyphenyl-(E)-3-(1H-indol-2-yl)acrylate (4j)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




2-Chlorophenyl-(E)-3-(1H-indol-2-yl)acrylate (4k)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




Methyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (**4j**)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




Ethyl-(E)-3-(1H-indol-2-yl)acrylate (4m):

¹H NMR, 500 MHz, DMSO-d₆




¹³C NMR, 125 MHz, DMSO-d₆




Pentyl-(E)-3-(1H-indol-2-yl)acrylate (4n)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




Phenethyl-(E)-3-(1H-indol-2-yl)acrylate (4o)

¹H NMR, 500 MHz, DMSO-d₆




¹³C NMR, 125 MHz, DMSO-d₆




(1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl-(*E*)-3-(1*H*-indol-2-yl)acrylate (4p)

¹H NMR, 500 MHz, CDCl₃




¹³C NMR, 125 MHz, CDCl₃




1,3,3-Trimethylbicyclo[2.2.1]heptan-2-yl-(E)-3-(1H-indol-2-yl)acrylate (4q)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




Methyl-(*E*)-3-(4-methyl-1H-indol-2-yl)acrylate (4r)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(4-(benzyloxy)-1*H*-indol-2-yl)acrylate (4s)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(4-bromo-1*H*-indol-2-yl)acrylate (**4t**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(5-methoxy-1*H*-indol-2-yl)acrylate (4u)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(5-chloro-1*H*-indol-2-yl)acrylate (**4v**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(5-bromo-1*H*-indol-2-yl)acrylate (**4u**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Methyl-(*E*)-2-(3-oxo-3-phenoxyprop-1-en-1-yl)-1*H*-indole-5-carboxylate (**4x**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(6-methoxy-1*H*-indol-2-yl)acrylate (4y)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(6-fluoro-1*H*-indol-2-yl)acrylate (**4z**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




Phenyl-(*E*)-3-(6-chloro-1*H*-indol-2-yl)acrylate (4a)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




3-Benzamido-3-(1*H*-indol-2-yl)propanoic acid (5a)


¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆



HSQC, DMSO- d_6




HMBC, DMSO- d_6




3-Benzamido-3-(4-methyl-1H-indol-2-yl)propanoic acid (5b)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




3-Benzamido-3-(5-methyl-1H-indol-2-yl)propanoic acid (5c)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




3-Benzamido-3-(5-methoxy-1H-indol-2-yl)propanoic acid (5d)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




3-Benzamido-3-(6-methyl-1H-indol-2-yl)propanoic acid (5g)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




3-Benzamido-3-(6-methoxy-1H-indol-2-yl)propanoic acid (5h)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




3-((Tert-butoxycarbonyl)amino)-3-(5-chloro-1H-indol-2-yl)propanoic acid (5i)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




3-((Tert-butoxycarbonyl)amino)-3-(5-bromo-1H-indol-2-yl)propanoic acid (5j)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




N-(4-Hydroxy-2-methylbutan-2-yl)benzamide (6)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




(E)-3-(6-Chloro-1H-indol-2-yl)acrylic acid (7)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$




N-Acetyl-*N*-methyl-1*H*-indole-1-carboxamide (**8**)

¹H NMR, 500 MHz, DMSO-*d*₆




¹³C NMR, 125 MHz, DMSO-*d*₆




5-Membered rhodacycle 9

^1H NMR, 500 MHz, CDCl_3




^{13}C NMR, 125 MHz, CDCl_3




2-Deutero-*N*-acetyl-1*H*-indole-1-carboxamide (1a-d)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$




^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$



2,7-Dideutero-*N*-acetyl-1*H*-indole-1-carboxamide (10)

^1H NMR, 500 MHz, $\text{DMSO-}d_6$



^{13}C NMR, 125 MHz, $\text{DMSO-}d_6$

